

(12)特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関  
国際事務局



(43) 国際公開日  
2003 年 10 月 23 日 (23.10.2003)

PCT

(10) 国際公開番号  
WO 03/087381 A1

(51) 国際特許分類: C12N 15/70, 15/53, 15/12,  
C12P 7/62 // C12N 15/53, 1/21, (C12N 15/70, C12R 1:04)  
(C12N 15/53, C12R 1:38) (C12N 15/12, C12R 1:465)  
(C12N 15/12, C12R 1:38) (C12P 7/62, C12R 1:19) (C12N  
1/21, C12R 1:19)

(21) 国際出願番号: PCT/JP03/04609

(22) 国際出願日: 2003 年 4 月 11 日 (11.04.2003)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:  
特願2002-110311 2002 年 4 月 12 日 (12.04.2002) JP

(71) 出願人 (米国を除く全ての指定国について): メルシヤ  
ン株式会社 (MERCIAN CORPORATION) [JP/JP]; 〒  
104-8305 東京都中央区京橋一丁目 5 番 8 号 Tokyo  
(JP).

(72) 発明者: および

(75) 発明者/出願人 (米国についてののみ): 有澤 章 (ARI-  
SAWA, Akira) [JP/JP]; 〒438-0078 静岡県磐田市 中泉  
1 7 9 7 ひかりハイツ 3 1 3 Shizuoka (JP). 久米田  
綾子 (KUMEDA, Ayako) [JP/JP]; 〒140-0011 東京都品  
川区 東大井 1-3-1 9-2 0 1 Tokyo (JP).

(74) 代理人: 小田島 平吉, 外(ODAJIMA, Heikichi et al.);  
〒107-0052 東京都港区赤坂 1 丁目 9 番 1 5 号 日本  
自転車会館 小田島特許事務所 Tokyo (JP).

(81) 指定国 (国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB,  
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,  
DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW.

(84) 指定国 (広域): ARIPO 特許 (GH, GM, KE, LS, MW, MZ,  
SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア特許 (AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許  
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,  
GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),  
OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

添付公開書類:

— 国際調査報告書

明細書とは別に規則 13 の 2 に基づいて提出された  
生物材料の寄託に関する表示。

2 文字コード及び他の略語については、定期発行される  
各 PCT ガゼットの巻頭に掲載されている「コードと略語  
のガイダンスノート」を参照。

(54) Title: EXPRESSION SYSTEM OF ACTINOMYCETE-ORIGIN CYTOCHROME P-450 IN *ESCHERICHIA COLI*

(54) 発明の名称: 大腸菌における放線菌由来チトクローム P-450 遺伝子の発現系

(57) Abstract: It is intended to provide an expression system of cytochrome P-450 with the use of *Escherichia coli* as a host. An *E. coli* strain containing a ferredoxin gene originating in actinomycete, a ferredoxin gene foreign to *E. coli* and a ferredoxin reductase gene, which is useful in the progress of an effective reaction of adding monoatomic oxygen to an organic compound serving as a substrate, is provided.

(57) 要約: 宿主大腸菌を用いるチトクローム P-450 遺伝子の発現系の提供。放線菌由来のフェレドキシン遺伝子、ならびに大腸菌に対して異種のフェレドキシン遺伝子およびフェレドキシン還元酵素遺伝子を含む大腸菌が提供される、基質有機化合物の効果的な一原子酸素添加反応を進めるのに有用である。

WO 03/087381 A1

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 500 704 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

**26.01.2005 Bulletin 2005/04**

(21) Application number: **03723103.2**

(22) Date of filing: **11.04.2003**

(51) Int Cl.7: **C12N 15/70, C12N 15/53, C12N 15/12, C12P 7/62**  
**// (C12N15/53, 1:21, 15:70), C12R1:04, C12N15:53, C12R1:38, C12N15:12, C12R1:465, C12N15:12, C12R1:38, C12P7:62, C12R1:19, C12N1:21, C12R1:19**

(86) International application number:

**PCT/JP2003/004609**

(87) International publication number:

**WO 2003/087381 (23.10.2003 Gazette 2003/43)**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

**AL LT LV MK**

(30) Priority: **12.04.2002 JP 2002110311**

(71) Applicant: **MERCIAN CORPORATION**  
**Chuo-ku, Tokyo 104-8305 (JP)**

(72) Inventors:

- **ARISAWA, Akira**  
**Iwata-shi, Shizuoka 438-0078 (JP)**
- **KUMEDA, Ayako**  
**Tokyo 140-0011 (JP)**

(74) Representative: **Hiebl, Inge, Dr.**  
**Kraus & Weisert**  
**Patent- und Rechtsanwälte**  
**Thomas-Wimmer-Ring 15**  
**80539 München (DE)**

(54) **EXPRESSION SYSTEM OF ACTINOMYCETE-ORIGIN CYTOCHROME P-450 IN ESCHERICHIA COLI**

(57) This invention relates to a system for the expression of cytochrome P-450 gene in host *Escherichia coli*, and provides *Escherichia coli* which contains actinomycete ferredoxin gene and also ferredoxin gene and ferredoxin reductase gene which are xenogenic to *Es-*

*cherichia coli*.

Thus, this invention is useful for the promotion of effective single oxygen atom insertional reaction of a substrate organic compound.

## Description

## Technical Field

5 [0001] This invention relates to a system for the expression of actinomycete cytochrome P-450 genes in *Escherichia coli*.

## Background Technology

10 [0002] Cytochrome P-450 enzymes (hereinafter referred to simply as "P-450s") which are encoded by cytochrome P-450 genes are a general name of a group of protoheme-containing proteins whose reduced form shows Soret band around 450 nm when bound to carbon monoxide. P-450s are bound to microsome in tissue of various kinds of animal or plant, or in fungi or yeasts, or to inner membrane of mitochondrion in tissue of some kind of animals. In certain kinds of bacteria and fungi, P-450s exist in soluble state.

15 [0003] P-450s show various types of substrate-specificity. Some P-450s have abnormally so wide substrate-specificity that they can react with various kinds of organic compounds as substrate. Some, on the other hand, have considerably strict substrate-specificity, and react only with comparatively limited kinds of organic compounds. P-450s also show excellent stereo- and/or regio-specificity to reaction site. With regard to concrete functions, P-450s are known to catalyze reactions such as hydroxylation, epoxidation, dealkylation and denitrification, of xenobiotics in a cell which  
20 expresses said P-450s. For example, most of drugs which are administered to human are metabolized and inactivated in the body by various or specific action, such as hydroxylation, of P-450. In some cases, on the contrary, pharmacological effects of the drugs are improved, or subsidiary action is enhanced. P-450 is, therefore, medically very important from the viewpoint of the research of metabolism of medicine or the development of prodrugs.

25 [0004] Thus, P-450s which have drug-metabolizing functions for higher organisms including human have been studied from every angle for long years. Although these enzymes are obtained from microsome fractions of liver of higher organisms, it is difficult to purify these enzymes into single isozyme. On this account, there has been developed a technology to express functionally a gene which encodes single isozyme in a host such as *Escherichia coli* or yeast, and to thus conveniently investigate the metabolic role of the enzyme.

30 [0005] P-450s of higher organisms which have such drug-metabolizing functions as mentioned above have never been successfully applied to material production on industrial scale. P-450s of higher organisms, when functionally expressed in a host such as *Escherichia coli* or yeast, show only low productivity as compared with P-450s of bacteria, and also cause various side reactions. For these reasons, P-450s of higher organisms have been used only restrictively.

35 [0006] In the case of P-450 originated from microorganisms such as fungi and bacteria, on the other hand, some kinds of P-450s are known to serve for the production of industrially useful materials. Some of such kinds of P-450s have actually been utilized for industrial production of useful medicine. Typical example is the production of pravastatin, a medicine to remedy hyperlipidemia, by means of the hydroxylation at 6 $\beta$ -position of compactin with *Streptomyces carbophilus*, a species of actinomycete (Watanabe et al., Gene, 163 (1995) 81-85, Japanese Patent Application Laid-Open (Kokai) Publication No. Hei 6 (1994)-70780). There has also been put into practice a method by which to produce active vitamin D<sub>3</sub> by means of the hydroxylation at 1 $\alpha$ - and 25-positions of vitamin D<sub>3</sub> with use of *Pseudonocardia autotrophica*, a species of actinomycete.  
40

[0007] Such microbial conversion of drugs with use of actinomycete cytochrome P-450 enzymes as mentioned above have been carried out with use of culture liquids or cells of actinomycetes which express said enzymes. There have also been used culture liquids wherein genes which encode actinomycete P-450s have been introduced into *Streptomyces lividans*, that is also a species of actinomycete and that is suitable as a host, to express the enzymatic activity.  
45 The microbial conversion of substrate compounds with the actinomycete strains which have such genes as mentioned above takes considerable time for the cultivation of the strains and for the conversion of substrate compounds into desired products. Furthermore, some enzymes need consideration on expression-inducible conditions under which to increase the amount of enzyme expressed. Moreover, some species of actinomycetes which are to be used for the conversion have, in themselves, a system for metabolizing or degrading substrate or desired product, which causes  
50 the formation of by-products or the reduction of substrate or desired product, and thus decreases the productivity of desired product.

[0008] There is also a report of experiment wherein, after the example of functionally expressing a gene which encodes single isozyme of the above-mentioned higher organism-originated P-450s in a host of microorganism such as *Escherichia coli*, CYP105D1 gene which is a *Streptomyces griseus* originated cytochrome P-450 gene was functionally expressed in *Escherichia coli* (Taylor et al., Biochemical and Biophysical Research Communications (1999) 263: 838-842). It seems that, in this expression system, some suitable electron donor for the P-450 in periplasm of *Escherichia coli* hydroxylates hydrocarbons in cooperation with the P-450 (Kaderbhai et al., Applied and Environmental Microbiology, 67 (2001) 2136-2138). Such a P-450 gene-expressing system has a merit that *Escherichia coli* as a host  
55

needs less time for cultivation as compared with actinomycetes or the like.

#### Disclosure of Invention

**[0009]** The above-mentioned system for the conversion of organic compounds with microorganisms which have P-450s is intended to be used, for instance, for the application to biocatalyst or for the research of drug metabolism. In consideration of application to biocatalyst, in particular, more efficient bioconversion would be demanded. In order to achieve the efficient screening of industrially important and desired actinomycete P-450 enzymes, there would be needed a suitable gene library as an object of robotized enzyme-assaying operation or other convenient and rapid enzyme-assaying operation in high throughput screening or the like. Concretely, there is demanded a library which has actinomycete-originated different cytochrome P-450 genes (actinomycete cytochrome P-450-expression library) and wherein microorganism, preferably handy and quick-growing microorganism, is used as a host in which each constituent clone is capable of expression.

**[0010]** In order to attain the above-mentioned objective, it would be useful to use, as a host, *Escherichia coli* which, at least, needs comparatively short time for cultivation, and which is considered to have only a few systems for the metabolism or degradation of substrate compounds or products from said substrate compounds. It has been confirmed, however, that only introducing an actinomycete P-450 gene into a host *Escherichia coli* and cultivating the same, as in the above-mentioned Taylor *et al.* wherein *Escherichia coli* is used as a host, does not achieve the functional expression of most of various kinds of P-450 genes which are originated from other species of actinomycete (or, in other words, enzymatic activity of P-450 is not shown as expected). Thus, the inventors of the present invention have studied how to construct a system which is capable of functionally expressing actinomycete-originated various kinds of P-450 genes surely and with high enzymatic activity. As a result, they have found out that, when a certain electron transport system originated from microorganism which is xenogenic to *Escherichia coli* is introduced together with P-450 gene and is then allowed to co-express, the P-450 gene originated from various species of actinomycete is functionally expressed.

**[0011]** Based on such a finding as mentioned above, this invention provides a system for the expression of actinomycete cytochrome P-450 genes in host *Escherichia coli*, wherein said *Escherichia coli* supports a recombinant DNA molecule which comprises xenogenic microorganism-originated ferredoxin gene, ferredoxin reductase gene and said cytochrome P-450 gene in operable state.

**[0012]** Such an expression system as explained above is capable of the expression of such a gene as mentioned in the above Taylor *et al.* which encodes actinomycete cytochrome P-450, and which is incapable of conjugating native electron transport system of *Escherichia coli*. In other words, the expression system of this invention achieves expected enzymatic activity of P-450 whether P-450 gene may conjugate native electron transport system of *Escherichia coli* or not. Thus, the term "functionally express" in this specification means that, a gene of interest expresses protein, which is encoded by the gene, in an active form.

**[0013]** In the following, this invention is explained in more detail.

**[0014]** Host *Escherichia coli* means certain kinds of *Escherichia coli* which are usable for the propagation of vectors such as plasmids and phages and of inserted genes. Any species of host will do if only, in a recombinant DNA experiment with use of host-vector system, a vector with an exogenous DNA fragment is capable of replication after transformation. As a host for said host-vector system, *Escherichia coli* on the market would be conveniently utilized.

**[0015]** Actinomycete cytochrome P-450 genes in this invention include P-450 genes originated from any genus of bacteria that belong to order *Actinomycetales* if only the bacteria have P-450 genes which serve to achieve the objective of this invention in some form or other (e.g., on chromosome or plasmid). Thus, cytochrome P-450 genes include all that encodes protein mentioned above which has such activity as to catalyze single oxygen atom insertional reaction in accordance with this invention. Although not restrictive, examples of P-450 genes which are intended to be incorporated into the expression system of this invention include those which have the above-mentioned function, at least a part of whose DNA sequences have been determined, and each of whose sequence information is available from gene data base (EMBL and GenBank), concretely, those which are originated from the following species of actinomycete and which encode protein having the above-mentioned activity, or those which have functions of cytochrome P-450 as mentioned below.

Actinomycete	Function of cytochrome P-450
<i>Amycolatopsis orientalis</i>	Unknown
<i>Actinomadura verrucosospora</i>	Biosynthesis of vercopeptin
<i>Amycolata autotrophica</i>	Unknown
<i>Amycolatopsis mediterranei</i>	Biosynthesis of rifamycin

(continued)

	Actinomycete	Function of cytochrome P-450
5	<i>Amycolatopsis mediterranei</i>	Biosynthesis of balhimycin
	<i>Kitasatospora griseospola</i>	Biosynthesis of terpentecin
	<i>Micromonospora griseorubida</i>	Biosynthesis of mycinamicin
	<i>Micromonospora inyoensis</i>	Unknown
	<i>Microtetraspora recticatena</i>	Hydroxylation of compactin
10	<i>Mycobacterium smegmatis</i> mc2155	Degradation of piperidine and pyrrolidine
	<i>Mycobacterium</i> sp. FM10	Unknown
	<i>Mycobacterium tuberculosis</i> H37Rv	22 P-450 genes in whole genome (function unknown)
	<i>Myxococcus xanthus</i>	Polyketide antibiotic TA
15	<i>Pseudonocardia autotrophica</i> (old name: <i>Amycolata autotrophica</i> )	Hydroxylation of vitamin D <sub>3</sub>
	<i>Rhodococcus erythropolis</i>	Degradation of thiocarbamate herbicide
	<i>Rhodococcus fascians</i> (D 188)	Synthesis of phytophysiologically active substance
	<i>Rhodococcus ruber</i>	Degradation of ethyl- <i>tert</i> -butyl ether
20	<i>Saccharopolyspora erythraea</i>	Hydroxylation of erythromycin
	<i>Streptoalloteichus hindustanus</i>	Unknown
	<i>Streptomyces acidiscabies</i>	Biosynthesis of thaxtomin A
	<i>Streptomyces albus</i>	Unknown
	<i>Streptomyces ansochromogenes</i>	Biosynthesis of nikkomycin
25	<i>Streptomyces antibioticus</i>	Biosynthesis of oleandomycin
	<i>Streptomyces antibioticus</i>	Biosynthesis of simocyclinone
	<i>Streptomyces aureofaciens</i> Re n 71	Unknown
	<i>Streptomyces avermitilis</i>	Formation of furan ring of avermectin
30	<i>Streptomyces avermitilis</i>	Biosynthesis of oligomycin
	<i>Streptomyces avermitilis</i>	Biosynthesis of polyketide-4
	<i>Streptomyces avermitilis</i>	Biosynthesis of polyketide-9
	<i>Streptomyces avermitilis</i>	Biosynthesis of other type polyketide
35	<i>Streptomyces avermitilis</i>	Biosynthesis of polyene macrolide
	<i>Streptomyces avermitilis</i>	Biosynthesis of peptide-7
	<i>Streptomyces carbophilus</i>	Hydroxylation of compactin
	<i>Streptomyces clavuligerus</i>	Biosynthesis of clavulanic acid
40	<i>Streptomyces coelicolor</i> A3(2)	18 P-450 genes in whole genome (function unknown)
	<i>Streptomyces fluvus</i>	Hydroxylation of compactin
	<i>Streptomyces fradiae</i>	Biosynthesis of tylosin
	<i>Streptomyces glaucescens</i>	Unknown
45	<i>Streptomyces griseolus</i>	Degradation of sulfonyleurea herbicide
	<i>Streptomyces griseus</i>	Unknown
	<i>Streptomyces hygroscopicus</i>	Biosynthesis of rapamycin
	<i>Streptomyces hygroscopicus</i> var. <i>ascomyceticus</i>	Biosynthesis of FK520
50	<i>Streptomyces lavendulae</i>	Biosynthesis of mitomycin
	<i>Streptomyces la vendulae</i>	Biosynthesis of complestatin
	<i>Streptomyces lividans</i>	Unknown
	<i>Streptomyces maritimus</i>	Biosynthesis of enterocin
	<i>Streptomyces natalensis</i>	Biosynthesis of pimaricin
55	<i>Streptomyces nodosus</i>	Biosynthesis of amphotericin
	<i>Streptomyces nogalater</i>	Biosynthesis of nogalamycin
	<i>Streptomyces noursei</i>	Biosynthesis of nystatin

(continued)

Actinomycete	Function of cytochrome P-450
<i>Streptomyces peucetius</i>	Hydroxylation of daunomycin
<i>Streptomyces peucetius subsp. caesius</i>	Hydroxylation of daunomycin
<i>Streptomyces rishiriensis</i> strain DSM 40489	Biosynthesis of coumermycin A1
<i>Streptomyces sclerotialus</i>	Unknown
<i>Streptomyces</i> sp.	Hydroxylation of FK-506
<i>Streptomyces</i> sp.	Unknown
<i>Streptomyces spheroids</i>	Biosynthesis of novobiocin
<i>Streptomyces tendae</i>	Biosynthesis of nikkomycin
<i>Streptomyces thermotolerans</i>	Epoxidation of carbomycin
<i>Streptomyces venezuelae</i>	Biosynthesis of pikromycin, methymycin

**[0016]** The following actinomycete P-450 are also included as usable in this invention. Each of the following literatures gives guidance how to prepare gene which encodes each enzyme.

Compactin-hydroxylating enzyme originated from <i>Streptomyces carbophilus</i> (P-450 <sub>sca</sub> -2)	Watanabe et al., Gene 163 (1995) 81-85 or Japanese Laid-Open (Kokai) Patent Publication No. Hei 6 (1994)-70780
<i>Microtetraspora recticatena</i>	Japanese Laid-Open (Kokai) Patent Publication No. 2001-286293
Vitamin D <sub>3</sub> -hydroxylating enzyme originated from <i>Amycolata</i> sp.	Sasaki et al., Applied Microbiology and Biotechnology (1992) 38: 152-157

**[0017]** *Streptomyces roseochromogenes*-originated progesterone-hydroxylating enzyme (Berrie et al., Journal of Steroid Biochemistry & Molecular Biology 77 (2001) 87-96) can also be mentioned. Although gene sequence of this *Streptomyces roseochromogenes* is not mentioned in published literatures, function and biochemical properties of this P-450 enzyme have detailedly determined, and, on the basis of which information, it is easy to prepare gene which encodes said P-450 enzyme.

**[0018]** Cytochrome P-450-encoding genes (or P-450 genes) as mentioned in this invention include any gene so long as it can be isolated from total DNAs of the above-mentioned actinomycetes or can be amplified by PCR reaction, which is mentioned later, on the basis of information of nucleotide sequences of said total DNAs, and so long as it is capable of functional expression in the system of this invention for the expression of P-450 genes. Also included in P-450 genes of this invention are polynucleotides which are functionally equivalent to the above-mentioned genes (also called native gene), and which have activity to catalyze single oxygen atom insertional reaction against corresponding substrates in the expression system of this invention. It is guessed that complement base sequences of said equivalent polynucleotides hybridize with corresponding native genes under a certain hybridization condition, e.g., under stringent condition in  $2 \times \text{SSC}$  (standard saline citrate) at 60°C, preferably in  $0.5 \times \text{SSC}$  at 60°C, most desirably  $0.2 \times \text{SSC}$  at 60°C. When each of the polynucleotides is lined up side by side with the corresponding native gene, there would be shown homology of 80 %, preferably 90 %, most desirably at least about 95 %. This "% homology" means percentage of nucleotide which is in common between two sequences when the two sequences are lined up side by side with each other in an optimum manner. [Thus, "% homology" = (number of coincident positions/total number of positions) x 100. This can be calculated with use of algorithm on the market. Such an algorithm is incorporated in NBLAST and XBLAST programs which are mentioned in Altschul et al., J. Mol. Biol. 215 (1990) 403-410.]

**[0019]** Ferredoxin gene which is incorporated in the expression system of this invention is a DNA molecule which is originated from microorganisms (or bacteria) which are xenogenic to host *Escherichia coli*. Ferredoxin gene generally encodes protein which functions as an electron transporter having a molecular weight of about 6,000 to 14,000. Ferredoxin gene may be originated from any bacteria except *Escherichia coli* so long as the bacteria participate in the functional expression of P-450 gene when co-expressed with the above-mentioned actinomycete P-450 gene and further with ferredoxin reductase gene which will be mentioned later. Concrete examples of said bacteria, although not restrictive, include actinomycete which may or may not be the same as mentioned above from which P-450 gene is originated.

[0020] Also usable is ferredoxin gene originated from bacteria, e.g., of genus *Pseudomonas*, which belong to different genus from that of actinomycete from which P-450 gene is originated. Examples of such a ferredoxin gene include putidaredoxin gene (also called *camB*) as mentioned in Peterson *et al.*, The Journal of Biological Chemistry, 265 (1990) 6066-6073.

[0021] When ferredoxin gene is originated from the same actinomycete from which P-450 gene is originated, P-450 gene and ferredoxin gene may sometimes constitute a gene cluster in which said P-450 gene and ferredoxin gene exist adjacent to each other on genomic DNA. In such a case, a DNA fragment which contains both of said genes may be used in the expression system of this invention. In the expression system of this invention, ferredoxin gene may exist with another ferredoxin. A preferable example of such a case is the use of ferredoxin gene originated from actinomycete in combination with the above-mentioned *camB* originated from *Pseudomonas putida*. Such a ferredoxin gene also includes functionally equivalent polynucleotide which can be specified in the same manner as in the above-mentioned P-450 gene.

[0022] Ferredoxin reductase gene which is incorporated in the expression system of this invention as an essential factor may be originated from bacteria which are xenogenic to host *Escherichia coli*, and which, under circumstances, may also be xenogenic to the origin of P-450 gene. Concretely, ferredoxin reductase gene originated from any bacteria is usable in this invention so long as the bacteria are capable of co-expression with the above-mentioned P-450 gene and with ferredoxin gene, and so long as the gene encodes ferredoxin reductase which shows the expected activity of P-450 enzyme, i.e., the product of said gene expression of P-450, or, in other words, which catalyzes single oxygen atom insertional reaction against substrate. Examples of such ferredoxin reductase gene, although non-restrictive, include ferredoxin reductase gene originated from *Streptomyces coelicolor* (hereinafter sometimes referred to as "fdr-1" or "fdr-2") and putidaredoxin reductase gene originated from the above-mentioned *Pseudomonas putida* (hereinafter referred to also as *camA*). Such a gene also includes functionally equivalent polynucleotide which can be specified in the same manner as in the above-mentioned P-450 gene.

[0023] In the expression system of this invention, the above-mentioned P-450 gene, ferredoxin gene and ferredoxin reductase gene are introduced in *Escherichia coli* in an operable state. The term "operable state" means that said genes are present in host in such a manner that all of the genes are capable of functional expression. In a typical example of such a state, all of the above-mentioned genes exist in a plasmid, which is capable of autonomous replication in *Escherichia coli*, together with autonomously replicating sequence, promoter sequence, terminator sequence and drug resistant gene, in a suitable order. Otherwise, all of said genes exist in chromosome of host *Escherichia coli* in such a manner that they are capable of functional expression via a chromosomal DNA integrative vector. The above-mentioned P-450 gene, ferredoxin gene and ferredoxin reductase gene may be arranged in any order in said plasmid. Usually, however, P-450 gene is preferably placed uppermost in the stream. When, in particular, P-450 gene and ferredoxin gene are used as a gene cluster fragment of the same origin, the following orders may be preferable: P-450 gene-ferredoxin gene-ferredoxin reductase gene; P-450 gene-ferredoxin gene-putidaredoxin reductase gene-putidaredoxin gene; or P-450 gene-putidaredoxin reductase gene-putidaredoxin gene.

[0024] Plasmid or vector which is usable in the above-mentioned expression system may be capable of stable autonomous replication in *Escherichia coli*, or may be an integrative vector which is capable of integrating chromosome of *Escherichia coli* with exogenous gene. Both can be available from those on the market, or by modification where necessary. Plasmids which have a strong promoter for gene transcription are conveniently used for the above-mentioned purpose. Examples of such plasmids include those on the market, such as pET11 and pUC18.

[0025] Thus provided actinomycete P-450 gene expression system of this invention is usable for the screening of P-450 enzymes which are suitable for the modification of various kinds of drugs or the bioconversion from precursor into desired drugs, or further for the manufacture of desired drugs from precursor.

#### Brief Explanation of Drawings

##### [0026]

Fig. 1 shows the structure of plasmid pMoxAB.

Fig. 2 shows the structure of plasmid pMoxAB-fdr1.

Fig. 3 shows the structure of plasmid pMoxAB-fdr2.

Fig. 4 shows the structure of plasmid pMoxAB-camAB.

Fig. 5 shows the structure of plasmid pT7NS-camAB.

Fig. 6 shows the structure of plasmid pCBM-camAB.


Fig. 7 shows the structure of plasmid pSC154A1-camAB.

Fig. 8 shows the structure of plasmid pDoxA1-camAB.



[0027] In the following, this invention is concretely explained with working examples.


Best Mode for Working this Invention

[0028] This invention will be further explained with reference to examples of the construction of P-450 gene which forms pravastatin of the following formula:




or a mixture (which is called "RT-5.8 substances" in this specification) of isomers thereof which have the following formulae:





by means of single oxygen atom insertional reaction of compactin of the following formula:



(or also existent as  $\delta$ -lactone compound corresponding to the above formula) or a salt thereof.

**[0029]** Incidentally, pravastatin sodium is a clinically important medicine as an agent to cure hyperlipidemia.

**[0030]** Actinomycete which has an enzymatic activity to hydroxylate compactin (also called mevastatin) belongs to genus *Streptomyces* (Japanese Laid-Open (Kokai) Patent Publication Sho 57 (1982)-50894, Japanese Patent No. 2672551) or to genus *Microtetraspora*. As for the latter, which has been confirmed by the inventors of this invention, a DNA fragment which contains P-450 gene can be prepared by the following process.

#### Preparation of P-450 gene from *Microtetraspora recticatena* IFO 14525

**[0031]** Said gene can be obtained by polymerase chain reaction (PCR) with use of primers which have been designed in accordance with an amino acid sequence of the region which is known to keep amino acid sequence with a high probability among a family of lot of P-450 hydroxylation enzymes (J. Bacteriol. 172, 3335-3345 (1990)). For example, IFO 14525 strain is cultivated under certain cultivation conditions, and, then, thus obtained cells are crushed to give chromosomal DNA. Thus obtained chromosomal DNA is subjected to PCR reaction with use of primers which have been designed from amino acid sequences for oxygen-binding domain and heme-binding domain which exist in common with P-450 hydroxylation enzyme family. There is obtained a DNA fragment which has been amplified by the PCR reaction, on the basis of which a further PCR reaction is conducted, and, thus, there is obtained flanking regions of the DNA fragment which has been amplified by the first PCR reaction (in the downstream, there existed a gene which encoded ferredoxin). All of the above-mentioned manipulation can be carried out by any method that is known well in this art. Details of these sets of manipulation are mentioned in the specification of Japanese Patent Application No. 2001-47664 by the same applicant as that of the present application (the contents of said specification are incorporated into the present specification by citation). Sequence No. 1 in the sequence listing shows a nucleotide sequence (and amino acid sequences encoded) which includes adjacent region of thus obtained P-450 gene.

**[0032]** In the above-mentioned sequence, a continuous nucleotide sequence from base 313 to base 1533 corresponds to P-450 gene (*moxA*), and a continuous nucleotide sequence from base 1547 to base 1741 corresponds to ferredoxin gene (*moxB*).

Preparation of P-450 gene from *Streptomyces* sp. TM-6 or TM-7

[0033] From among a lot of microorganisms that belong to *Streptomyces* which were isolated from the soil in Japan, the applicant has identified the above-captioned TM-6 and TM-7 strains as microorganisms which are capable of biologically converting compactin as a substrate into pravastatin. Said strains were deposited on April 25, 2001, at the International Patent Organism Depository (IPOD) in the National Institute of Advanced Industrial Science and Technology (AIST) at Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan, and thus have been received with Deposit Nos. FERM P-18311 and FERM P-18312.

[0034] Later, a demand was made on the above-mentioned IPOD, which is also an international depositary authority under the Budapest Treaty, for the transfer of these strains TM-6 and TM-7 to said international depositary authority under said Treaty, and, thus, these strains have been received with Deposit Nos. FERM BP-8002 and FERM BP-8003.

[0035] With regard to said TM-7 strain, a region of target gene was amplified by PCR in the same manner as in the above-mentioned IFO 14525, and, thus, the sequence of DNA fragment containing the target gene and its adjacent region was determined. The result is shown in Sequence No. 2. In this sequence, a continuous nucleotide sequence from base 544 to base 1758 corresponds to P-450 gene (*boxA*), and a continuous nucleotide sequence from base 1782 to base 1970 corresponds to ferredoxin gene (*boxB*). The manipulation to obtain these genes is mentioned detailedly in the specification of Japanese Patent Application No. 2001-166412 which has been filed by the applicant of the present application (the contents of said specification are incorporated into the present specification by citation).

[0036] When compared with the sequence of P-450 gene of *Streptomyces carbophilus* SANK 62585 strain (FERM BP-1145) which is mentioned, for instance, in Japanese Patent No. 2672551, the nucleotide sequence of the above-mentioned *boxA* was found to have a homology of about 75 %. With the above-mentioned *moxA*, the *boxA* has a homology of about 46 %. With hydroxylation enzyme gene of *Streptomyces lividans*, the *boxA* has a homology of about 75 %. Said *boxA* has a homology of about 46 % with a gene encoding pyridylhomothreonine monooxygenase which is an intermediate in the course of biosynthesis of nikkomycin by *Streptomyces tendae* Tji 901 strain.

[0037] On the basis of the above explanation or explanation in working examples mentioned below or, furthermore, on the basis of techniques which are known well in this art or of information in gene database, anyone skilled in the art would be able to obtain various kind of P-450 genes by means of firstly screening actinomycetes which are known (from type culture catalogue published by ATCC) with respect to bio-conversion of substrates for single oxygen atom insertion, then identifying strains having expected enzymatic activity, and thus conducting PCR operation as mentioned above. Hence, actinomycete cytochrome P-450 genes as called in this invention include not only known ones but also all that skilled persons could obtain.

[0038] The preparation of ferredoxin gene and ferredoxin reductase gene which are included in the expression system of this invention, and the construction of expression system by means of operable connection between these genes and P-450 genes, could be achieved quite easily by anyone skilled in the art in the same manner as in the above-mentioned P-450 genes, or in accordance with methods as mentioned in literatures (Sambrook *et al.*, Molecular Cloning, A Laboratory Manual, 3<sup>rd</sup> edition (2001), Cold Spring Harbor Laboratory Press, New York), and in the light of the methods in working examples as mentioned later.

[0039] Thus constructed expression system for P-450 genes is capable of functionally expressing P-450 genes under conditions where *Escherichia coli* is grown. When such an expression system is incubated under a suitable condition together with a substrate for enzyme as a product of P-450 gene (or when transformant as an expression system is cultivated), there is obtained a product wherein single oxygen atom has been inserted in substrate.

[0040] Cultivation is usually conducted on a medium which can be a nutritious medium for *Escherichia coli*, and which has no adverse effects on biological conversion of substrate. Such a medium is composed of suitable carbon source, nitrogen source, inorganic salt and natural organic nutriment. As said carbon source, there can be used glucose, fructose, glycerol, sorbitol and organic acids, either singly or in combination. The concentration of these carbon sources when used is suitably about 1 to 10 %, not particularly limited. As said nitrogen source, there can be employed one or two from ammonia, urea, ammonium sulfate, ammonium nitrate and ammonium acetate. As said inorganic salt, there can be used salts such as potassium dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium sulfate, manganese sulfate and ferrous sulfate. As organic nutrient which has growth promoting effects on microorganism used, there can be used peptone, meat extract, yeast extract, corn steep liquor and casamino acids. Furthermore, a small amount of vitamins and nucleic acids may be included in medium.

[0041] In the expression system of this invention, high-titer P-450 enzymes with expected activity can be obtained when P-450 enzymes are induced at a temperature of about 25°C or less, preferably at 20 to 24°C, after host *Escherichia coli* has been cultivated at a temperature suitable for the growth of *Escherichia coli*, e.g. at 28 to 40°C.

[0042] The following is a detailed explanation of an example of construction of expression system for *moxA* gene originated from *Microtetraspora recticatenata* IFO 14525 which encodes a compactin-hydroxylating enzyme as an instance of actinomycete cytochrome P-450 enzymes. This invention is, however, not restricted at all by this example.

Polymerase Chain Reaction (PCR):

[0043] In the following example, PCT is conducted under conditions as follows.

(1) Condition where genomic DNA is used as a template:

[0044]

(Composition of reaction liquid)	
Sterilized purified water	15 $\mu$ l
Twice-concentrated GC buffer I (Takara Shuzo)	25 $\mu$ l
dNTP mixed solution (dATP, dGTP, dTTP, dCTP each 2.5 mM)	8 $\mu$ l
Forward primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Reverse primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Genomic DNA (10 ng/ $\mu$ l)	0.5 $\mu$ l
LA Taq (5 units/ $\mu$ l Takara Shuzo)	0.5 $\mu$ l

(Temperature condition)	
94°C	3 minutes
(98°C 20 seconds; 63°C 30 seconds; 68°C 2 minutes) 30 cycles	
72°C	5 minutes

(2) Condition where plasmid DNA (pMoxAB-fdr1) is used as a template:

[0045]

(Composition of reaction liquid)	
Sterilized purified water	15 $\mu$ l
Twice-concentrated GC buffer I (Takara Shuzo)	25 $\mu$ l
dNTP mixed solution (dATP, dGTP, dTTP, dCTP each 2.5 mM)	8 $\mu$ l
Mox-3F primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Mox-5R primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Plasmid DNA (1 ng/ $\mu$ l)	0.5 $\mu$ l
LA Taq (5 units/ $\mu$ l Takara Shuzo)	0.5 $\mu$ l

(Temperature condition)	
94°C	3 minutes
(98°C 20 seconds; 63°C 30 seconds; 68°C 2 minutes) 25 cycles	
72°C	5 minutes

Example 1 Construction of plasmid

(1) pT7-fdr1

[0046] PCR was carried out with use of primer FDR1-1F (5'-GCCATATGACTAGTGCGCCTCACAGACTGGAACG-GGAATCTCATG -3') (see Sequence No. 3) and FDR1-2R (5'-GCGAATTCTGTCGGTCAGGCCTGGTCTCCCGTCG-GCCG-3') (see Sequence No. 4) by using, as a template, genomic DNA of *Streptomyces coelicolor* A3(2) [imparted by John Innes Institute (Norwich, UK)], and, thus, there was amplified a 1.3-kb fragment of gene (hereinafter referred

to as *fdr-1*; see Sequence No. 5) encoding a protein which has homology with ferredoxin reductases. This fragment was treated with restriction enzyme *Nde* I and *Bam* HI, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, the *fdr-1* gene fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said gene fragment, which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I site and *Bam* HI site of *Escherichia coli* plasmid vector pET11a (manufactured by Stratagene Co.) with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed with the resultant DNA reaction liquid, and, thus, pT7-fdr1 was constructed.

#### (2) pT7-fdr2

**[0047]** Under the same condition, PCR was carried out with use of primer FDR2-3F (5'-CGACTAGTGACGAGGAG-GCAGACAAATGGTCGACGCGGATCAG-3') (see Sequence No. 6) and FDR2-4R (5'-CGGGATCCGACAACTAT-GCGACGAGGCTTTGAGGG-3') (see Sequence No. 7) by using genomic DNA of the above-mentioned *Streptomyces coelicolor* A3(2), and, thus, there was amplified a 1.3-kb fragment of gene (hereinafter referred to as *fdr-2*, see Sequence No. 8), which is different from *fdr-1*, encoding a protein which has homology with ferredoxin reductases. This fragment was treated with restriction enzyme *Bam* HI and *Spe* I, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, *fdr-1* gene fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said gene fragment, which had been cut out from the gel, and was purified. Apart from that, plasmid pT7-fdr1 was treated with *Bam* HI and *Spe* I, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, pET11a vector fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said vector fragment which had been cut out from the gel, and was purified. Said vector fragment and the above-mentioned *fdr-1* gene fragment were ligated to each other with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, pT7-fdr2 was constructed.

#### (3) pT7-camAB

**[0048]** PCR was carried out with use of primer PRR-1F (5'-GCCCCCATATGAACGCAAACGACAACGTGGTCATC-3') (see Sequence No. 9) and PRR-2R (5'-GCGGATCCTCAGGCACTACTCAGTTCAGCTTTGGC-3') (see Sequence No. 10) by using, as a template, genomic DNA of *Pseudomonas putida* ATCC17453, and, thus, there was amplified a 1.65 kb fragment (*camAB* fragment; see Sequence No. 16) which contained putidaredoxin reductase gene (*camA*) and putidaredoxin gene (*camB*) which was just downstream of said *camA*. This fragment was treated with restriction enzyme *Nde* I and *Bam* HI, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, *camAB* fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said fragment, which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I site and *Bam* HI site of *Escherichia coli* plasmid vector pET11a (manufactured by Stratagene Co.) with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, pT7-camAB was constructed.

#### (4) pMoxAB

**[0049]** PCR was carried out with use of primer Mox-1F (5'-GCCGCCCATATGACGAAGAACGTGCGCCGACGAACTG-3') (see Sequence No. 11) and Mox-12R (5'-GCAGATCTAGTGGCTTCAGGCGTCCCGCAGGATGG-3') (see Sequence No. 12) by using, as a template, genomic DNA of IFO14525 strain, and, thus, there was amplified a 1.4-kb fragment (*moxAB* fragment) which contained a gene (*moxA*) encoding compactin-hydroxylation enzyme and ferredoxin gene (*moxB*) which was adjacent downstream thereto. This fragment was treated with restriction enzyme *Nde* I and *Bgl* II, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, *moxAB* fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said fragment, which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I site and *Bam* HI site of the above-mentioned plasmid pET11a with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed with resultant reaction liquid, and, thus, plasmid pMoxAB was constructed.

#### (5) pMoxAB-fdr1 and pMoxAB-fdr2

**[0050]** PCR was carried out with use of primer Mox-1F (5'-GCCCCCATATGACGAAGAACGTGCGCCGACGAACTG-3') (see Sequence No. 11 as mentioned above) and Mox-2R (5'-CGACTAGTGGCTTCAGGCGTCCCGCAGGATGG-3') (see Sequence No. 13) by using, as a template, genomic DNA of IFO14525 strain, and, thus, there was amplified a 1.4-kb fragment (*moxAB* fragment) which contained a gene (*moxA*) encoding compactin-hydroxylation enzyme and ferredoxin gene (*moxB*) which was adjacent downstream thereto. This fragment was treated with restriction enzyme *Nde* I and *Spe* I, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over,

*moxAB* fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said fragment, which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I site and *Spe* I site of the above-mentioned plasmid pT7-fdr1 with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed with resultant reaction liquid, and, thus, plasmid pMoxAB-fdr1 was constructed. Fig. 2 shows the structure of this pMoxAB-fdr1.

[0051] The same inserted fragment was ligated to *Nde* I site and *Spe* I site of another plasmid pT7-fdr2 with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed with resultant reaction liquid, and, thus, plasmid pMoxAB-fdr2 was constructed. Fig. 3 shows the structure of this pMoxAB-fdr2.

#### (6) pMoxAB-camAB

[0052] PCR was carried out with use of primer Mox-3F (5'-GGAGATATACATATGACGAAGAAC-3') (see Sequence No. 14) and Mox-5R (5'-GCCCCCATATGACGCACTCCTAGTGGCTTCAGGCGTCCCG-3') (see Sequence No. 15) by using, as a template, DNA of pMoxAB-fdr1, and, thus, there was amplified a 1.5-kb fragment which contained a gene encoding cytochrome P-450 enzyme having compactin-hydroxylating activity and ferredoxin gene (*moxAB*) which was adjacent downstream thereto. This fragment was ligated to *Nde* I site of the plasmid pT7-camAB with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed with resultant reaction liquid, and, thus, plasmid pMoxAB-camAB was constructed. Fig. 4 shows the structure of this pMoxAB-camAB.

#### Example 2 Preparation of recombinant which has actinomycete cytochrome P-450 enzymatic activity

[0053] *Escherichia coli* BL21(DE3) was transformed with three plasmids, i.e., pMoxAB-fdr1, pMoxAB-fdr2 and pMoxAB-camAB, and, thus, transformant strains corresponding to these plasmids were obtained. Single colony of each of these strains was seeded on 2 ml of LB medium, and was subjected to shake culture at 28°C for 16 hours at 220 rpm. Thus obtained culture liquid in an amount of 200  $\mu$ l was mixed with an equal amount (200  $\mu$ l) of 40 % glycerol (sterilized) to give a glycerol culture, which was preserved at -80°C until used. On the other hand, with use of pMoxAB and pET11a which was used as a vector, *Escherichia coli* BL21(DE3) was transformed, and, thus, transformant strains corresponding to these plasmids were obtained. Said transformant strains were used as control.

#### Example 3 Production of pravastatin and its hydroxylated analogues from compactin

##### (1) Production process with use of static cells:

[0054] Glycerol culture of transformant strain of BL21(DE3) as obtained in the above Example 2 in an amount of 10  $\mu$ l was added to 2 ml of LB medium to which 50  $\mu$ g/ml (final concentration) of ampicillin had been added, and was then subjected to shake culture at 28°C for 16 hours at 220 rpm. The resultant culture liquid in an amount of 250  $\mu$ l was added to 25 ml of NZCYM medium to which 50  $\mu$ g/ml (final concentration) of ampicillin had been added, and was then subjected to shake culture at 37°C for 2.5 hours. Then, 25  $\mu$ l of 100 mM IPTG and 25  $\mu$ l of 80 mg/ml 5-aminolevulinic acid were added in this order, and the resultant mixture was subjected to shake culture at 18-28°C (this temperature is hereinafter called as "induction temperature") for 16 hours at 120 rpm. Cells were recovered by centrifugation from 10 ml of the resultant culture liquid, and were then washed once with conversion buffer-2 (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM EDTA, 0.2 mM DTT, 10 % glycerol, [pH 7.3]). Subsequently, the cells were suspended in 1 ml of said buffer to give a suspension of static cells. To this suspension of static cells, there were added compactin sodium salt (final concentration 250  $\mu$ g/ml) and NADPH (final concentration 1 mM), and the resultant mixture was incubated at 32°C for 24-48 hours (this time is hereinafter referred to as "conversion time") under shaking condition (220 rpm). Later, to 100  $\mu$ l of thus obtained reaction liquid, there was added 100  $\mu$ l of acetonitrile, and the resultant mixture was subjected to vortex for one minute at room temperature, and was then centrifuged for 10 minutes at 16,000 rpm with an Ependorf centrifugator. So obtained supernatant was analyzed with HPLC, and, thus, there were detected pravastatin and other hydroxylated analogues which had been formed by the hydroxylation of substrate compactin. The following shows detailed condition for this HPLC.

Analytical apparatus	Shimadzu C-4RA Chromatopac
Column	J' sphere ODS-H80 (YMC, Inc.), 75 mm x 4.6 mm I.D.
Mobile phase A	Ion-exchange water/acetic acid/triethylamine = 998:1:1
B	Methanol/acetic acid/triethylamine = 998:1:1

5	Gradient time program	0 minute Mobile phase A/B = 50:50
		3.00 minute Mobile phase A/B = 10:90
		3.50 minute Mobile phase A/B = 10:90
		3.51 minute Mobile phase A/B = 50:50
		6.00 minute End

10  15	Flow rate	2.0 ml/minute
	Detection	UV 237 nm
	Injection content	10 µl
	Column temperature	40°C
	Analysis time	6 minutes
	Retention time	compactin      4.2 minutes pravastatin      2.7 minutes RT-5.8 substances      3.6 minutes

(2) Production process by Fed-batch method:

**[0055]** Glycerol culture of transformant strain of BL21(DE3) in an amount of 10 µl was added to 2 ml of LB medium to which 50 µg/ml (final concentration) of ampicillin had been added, and was then subjected to shake culture at 28°C for 16 hours at 220 rpm. The resultant culture liquid in an amount of 250 µl was added to 25 ml of M9-plus medium (M9 salt, 0.4 % glucose, 0.5 % casamino acids, 100 µg/ml thiamin, 20 µl/ml thymine, 0.1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>) to which 50 µg/ml (final concentration) of ampicillin had been added, and was then subjected to shake culture at 37°C for 2.5 hours. Then, 25 µl of 100 mM IPTG and 25 µl of 80 mg/ml 5-aminolevulinic acid were added in this order, and the resultant mixture was subjected to shake culture at 22°C for 16 hours at 120 rpm. To the resultant culture liquid, there was added 2.5 ml of conversion mixture (2.5 mg/ml compactin sodium salt, 1 mg/ml FeSO<sub>4</sub>·7H<sub>2</sub>O, 10 mM NADPH, 50 % glycerol), and, thus, cultivation was continued at 22°C for 96 hours. The period of time which has passed after the addition of this conversion mixture is hereinafter referred to as "cultivation time". Then, to 100 µl of this culture liquid, there was added 100 µl of acetonitrile, and the resultant mixture was subjected to vortex for one minute at room temperature, and was then centrifuged for 10 minutes at 16,000 rpm with an Epfendorf centrifugator. So obtained supernatant was analyzed with HPLC, and, thus, there were detected pravastatin and other hydroxylated analogues which had been formed by the hydroxylation of substrate compactin.

**[0056]** Table 1 shows results of the measurement of the amount of pravastatin and RT-5.8 substance produced by static cells as mentioned in Example 3(1) with use of *Escherichia coli* transformant strain, under the protein induction condition of 18-28°C and with a conversion time of 48 hours.

Table 1

Induction temperature	18°C		22°C		25°C		28°C	
	Pravastatin	RT-5.8 substances	Pravastatin	RT-5.8 substances	Pravastatin	RT5.8 substances	Pravastatin	RT-5.8 substances
Hydroxylated compactin (µg/ml)								
BL21(DE3)/ pET11a	0	0	0	0	0	0	0	0
BL21(DE3)/ pMoxAB	0	0.18	0	0	0	0	0	0.3
BL21(DE3)/ pMoxAB-fdr1	0.24	1.24	1.72	8.48	0.43	1.92	0	0.61
BL21(DE3)/ pMoxAB-fdr2	0.25	1.31	2.15	10.21	0	0.84	0.35	1.65
BL21(DE3)/ pMoxAB-camAB	3.84	22.07	6.09	33.55	4.05	16.53	0.97	5.49

**[0057]** Productivity was the highest when induction temperature was 22°C, under which condition each of strains wherein *Streptomyces coelicolor* A3(2)-originated ferredoxin reductase (*fdr-1* or *fdr-2*) had been co-expressed accumulated, in medium, 1.7 to 2.1 µg/ml of pravastatin and 8.4 to 10.2 µg/ml of RT-5.8 substances. A strain wherein *camAB* had been expressed showed much higher productivity; it accumulated, in medium, 6.09 µg/ml of pravastatin and 33.55 µg/ml of RT-5.8 substance. In the case where there was used, as control, vector alone (BL21(DE3)/pET11a) or a strain which contained no gene to encode ferredoxin reductase (BL21(DE3)/pMoxAB), there were hardly detected pravastatin and RT-5.8 substances.

**[0058]** Table 2 shows results of test of productivity of pravastatin in Fed-batch method as mentioned in Example 4 (2).

Table 2

Cultivation time	4 hours		24 hours		48 hours		96 hours	
	Pravastatin	RT-5.8 substances	Pravastatin	RT-5.8 substances	Pravastatin	RT-5.8 substances	Pravastatin	RT-5.8 substances
Hydroxylated compactin (µg/ml)								
BL21(DE3)/pET11a	0	0	0	0	0	0	0	0
BL21(DE3)/pMoxAB	0	0	0	0	0	0	0	0
BL21(DE3)/pMoxAB-fdr1	0	0	0	0	0	0.87	0	0.61
BL21(DE3)/pMoxAB-fdr2	0	0	0	0	0	0.29	0	0.28
BL21(DE3)/pMoxAB-camAB	0	0	0.28	2.82	0.64	7.74	0.95	12.44

[0059] In the results with cultivation time of 96 hours, strains wherein *Streptomyces coelicolor* A3(2)-originated ferredoxin reductase (*fdr-1* or *fdr-2*) had been co-expressed accumulated, in medium, 0.28 to 0.61 µg/ml of RT-5.8 substances while accumulating no pravastatin. A strain wherein *camAB* had been expressed showed high productivity; it accumulated, in medium, 0.95 µg/ml of pravastatin and 12.44 µg/ml of RT-5.8 substances. In the case where there was used, as control, vector alone (BL21(DE3)/pET11a) or a strain which contained no gene to encode ferredoxin reductase (BL21(DE3)/pMoxAB), pravastatin and RT-5.8 substances were not detected.

[0060] In a strain wherein *camAB* had been co-expressed, i.e., in *Escherichia coli* wherein pMoxAB-*camAB* had been introduced, *moxB* (ferredoxin gene) and *camB* (putidaredoxin gene) among thus introduced genes overlap with each other in their function. In order to know which gene among the constituent genes contained in said pMoxAB-*camAB* are indispensable for the expression of activity, the inventors of this invention constructed a plasmid which lacked one or two of said constituent genes, and introduced the plasmid into *Escherichia coli*. Table 3 shows results of productivity of hydroxylated compactin with use of static cells of thus prepared strain, and with a conversion time of 24 hours.

Table 3

	Constituent gene (+: existent; -: non-existent)				Hydroxylated compactin (µg/ml)	
	<i>moxA</i>	<i>moxB</i>	<i>camA</i>	<i>camB</i>	Pravastatin	RT-5.8 substances
BL21(DE3)/ pET11a	-	-	-	-	0	0
BL21(DE3)/ pMoxAB	+	+	-	-	0	0
BL21(DE3)/ pMoxAB- <i>camA</i>	+	+	+	-	0.17	0.82
BL21(DE3)/ pMoxA- <i>camAB</i>	+	-	+	+	0	0
BL21(DE3)/ pMoxAB- <i>camAB</i>	+	+	+	+	1.67	9.96

[0061] The above shows that three kinds of gene of *moxA*, *moxB* and *camA* are essential for the expression of activity, and that the addition of *camB* achieves a remarkable increase in activity; the yield of hydroxylated compactin increased about 10 times.

#### Example 5 Construction of plasmid

##### (1) pT7NS-*camAB*

[0062] PCR was carried out under the following condition with use of primer PRR-1F (5'-GCCCCCATATGAACG-CAAACGACAACGTGGTCATC-3') (see Sequence No. 9) and PRR-2R (5'-GCGGATCCTCAGGCACTACTCAGT-TCAGCTTTGGC-3') (see Sequence No. 10) by using, as a template, genomic DNA of *Pseudomonas putida* ATCC17453.

(Composition of reaction liquid)	
Sterilized purified water	15 µl
Twice-concentrated GC buffer I (Takara Shuzo)	25 µl
dNTP mixed solution (dATP, dGTP, dTTP, dCTP each 2.5 mM)	8 µl
PRR-1F primer (100 pmol/µl)	0.5 µl
PRR-2R primer (100 pmol/µl)	0.5 µl
<i>Pseudomonas putida</i> ATCC 17453 Genomic DNA (10 ng/µl)	0.5 µl
LA Taq (5 units/µl Takara Shuzo)	0.5 µl

(Temperature condition)	
95°C	3 minutes
(98°C 20 seconds; 63°C 30 seconds; 68°C 2 minutes) 30 cycles	
72°C	5 minutes

**[0063]** An amplified 1.5-kb fragment (*camAB* fragment) which contained ferredoxin reductase gene (*camA*) and putidaredoxin gene (*camB*) just downstream thereto was treated with restriction enzyme *Nde* I and *Bam* HI, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, *camAB* fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said gene fragment which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I site and *Bam* HI site of *Escherichia coli* plasmid vector pET11a (manufactured by Stratagene Co.) with use of T4 DNA ligase, and, then, *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, pT7-*camAB* was constructed. To *Nde* I site of said plasmid pT7-*camAB*, there was ligated by T4 DNA ligase one molecule of linker which had been prepared by the annealing of two kinds of synthetic oligo DNAs SP-1 (5'-TATGCGTCACTAGTCGGGAGTGCCTTA-3') (see Sequence No. 17) and SP-2 (5'-TATAACGCACTCCGACTAGTGACGCA-3') (see Sequence No. 18), with which *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, plasmid pT7NS-*camAB* was constructed. Fig. 5 shows the structure of pT7NS-*camAB*.

## (2) pCBM-*camAB*

**[0064]** PCR was carried out under the following condition with use of primer CB-4F (5'-GCCCCCATATGACAGCTTGAATCTGATG-3') (see Sequence No. 19) and CB-5R (5'-GCACTAGTCAGAGACGGACCGGCAGAC-3') (see Sequence No. 20) by using, as a template, total DNA of *Streptomyces thermotolerans* ATCC11416, and, thus, there was prepared 1.25 kb fragment of ORF-A (cytochrome P-450 gene which encodes enzyme to epoxidize 12- and 13-positions of carbomycin B) (gene sequence of ORF-A and the function of ORF-A are mentioned in Bioscience Biotechnology Biochemistry vol. 59, 582-588, 1995; the contents of this literature is incorporated into the present specification by this citation).

(Composition of reaction liquid)	
Sterilized purified water	61 $\mu$ l
10 times-concentrated buffer (Takara Shuzo)	10 $\mu$ l
25 mM $\text{MgCl}_2$	10 $\mu$ l
dNTP mixed solution (dATP, dGTP, dTTP, dCTP each 2.5 mM)	16 $\mu$ l
CB-4F primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
CB-5R primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Total DNA (100 ng/ $\mu$ l) of <i>Streptomyces thermotolerans</i> ATCC11416	1 $\mu$ l
LA Taq (5 units/ $\mu$ l, Takara Shuzo)	1 $\mu$ l

(Temperature condition)	
95°C	3 minutes
(98°C 20 seconds; 63°C 30 seconds; 68°C 2 minutes) 30 cycles	
72°C	5 minutes

**[0065]** This gene fragment was digested with restriction enzyme *Nde* I and *Spe* I, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, ORF-A fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said gene fragment, which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I-*Spe* I site of pT7NS-*camAB* with use of T4 DNA ligase, and, with the resultant reaction liquid, *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, plasmid pCBM-*camAB* was constructed. Fig. 6 shows the structure of pCBM-*camAB*.

## (3) pSC154A1-*camAB*

**[0066]** Total DNA of *Streptomyces coelicolor* A3(2) (imparted by John Innes Institute, Norwich, UK) was digested with restriction enzyme *Bam* HI and *Pst* I to give a 100 ng/ $\mu$ l solution of TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA). PCR was carried out under the following condition by using this DNA as a template with use of primer 154A1-1F (5'-GCCCCCATATGGCGACCCAGCAGCCCGCCCTC-3') (see Sequence No. 21) and 154A1-2R (5'-GCACTAGTCAGCCGGCGTGCAGCAGGACCGG-3') (see Sequence No. 22), and, thus, there was prepared 1.2 kb gene fragment which encoded CYP154A1 (DNA sequence of gene which encodes *Streptomyces coelicolor* A3(2)-originated CYP154A1 has been published in gene database, e.g., Gen Bank, under gene name of SCE6.21).

(Composition of reaction liquid)	
Sterilized purified water	61 $\mu$ l
10 times-concentrated buffer (Takara Shuzo)	10 $\mu$ l
25 mMgCl <sub>2</sub>	10 $\mu$ l
dNTP mixed solution (dATP, dGTP, dTTP, dCTP each 2.5 mM)	16 $\mu$ l
154A1-1F primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
154A1-2R primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Total DNA (100 ng/ $\mu$ l) of <i>Streptomyces coelicolor</i> A3(2) digested with <i>Bam</i> HI- <i>Pst</i> I	1 $\mu$ l
LA Taq (5 units/ $\mu$ l, Takara Shuzo)	1 $\mu$ l

(Temperature condition)	
95°C	3 minutes
(98°C 20 seconds; 63°C 30 seconds; 68°C 2 minutes) 30 cycles	
72°C	5 minutes

**[0067]** This gene fragment was digested with restriction enzyme *Nde* I and *Spe* I, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, CYP154A1-encoding gene fragment was recovered, with use of SUPREC-01 (Takara Shuzo), from a gel piece containing said gene fragment which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I-*Spe* I site of pT7NS-camAB with use of T4 DNA ligase, and, with the resultant reaction liquid, *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, plasmid pSC154A1-camAB was constructed. Fig. 7 shows the structure of pSC154A1-camAB.

#### (4) pDoxA1-camAB

**[0068]** PCR was carried out under the following condition with use of primer DoxA-1F (5'-GCCCCCATATGGCCGTC-GACCCGTTTCGCGTG-3') (see Sequence No. 23) and DoxA-2R (5'-GCACTAGTCAGCGCAGCCAGACGGGCAGTTC-3') (see Sequence No. 24) by using, as a template, total DNA of daunomycin-producing bacterium *Streptomyces peucetius* ATCC 29050, and, thus, there was prepared 1.2-kb fragment of *doxA* (cytochrome P-450 gene which participates in the biosynthesis of daunomycin). DNA sequence of the *doxA* gene is mentioned in Journal of Bacteriology, vol. 181, No. 1, 305-318, 1999 (the contents of this literature is incorporated into the present specification by this citation).

(Composition of reaction mixture)	
Sterilized purified water	61 $\mu$ l
10 times-concentrated buffer (Takara Shuzo)	10 $\mu$ l
25 mMgCl <sub>2</sub>	10 $\mu$ l
dNTP mixed solution (dATP, dGTP, dTTP, dCTP each 2.5 mM)	16 $\mu$ l
DoxA-1F primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
DoxA-2R primer (100 pmol/ $\mu$ l)	0.5 $\mu$ l
Total DNA (100 ng/ $\mu$ l) of <i>Streptomyces peuceticus</i> ATCC 29050	1 $\mu$ l
LA Taq (5 units/ $\mu$ l, Takara Shuzo)	1 $\mu$ l

(Temperature condition)	
95°C	3 minutes
(98°C 20 seconds; 63°C 30 seconds; 68°C 2 minutes) 30 cycles	
72°C	5 minutes

**[0069]** This gene fragment was digested with restriction enzyme *Nde* I and *Spe* I, and was then subjected to electrophoresis in 0.8 % agarose gel. After the electrophoresis was over, *doxA* fragment was recovered, with use of SU-PREC-01 (Takara Shuzo), from a gel piece containing said gene fragment which had been cut out from the gel, and was purified. Said fragment was ligated to *Nde* I-*Spe* I site of pT7NS-camAB with use of T4 DNA ligase, and, with the resultant reaction liquid, *Escherichia coli* DH5 $\alpha$  was transformed, and, thus, plasmid pDoxA1-camAB was constructed. Fig. 8 shows the structure of pDoxA1-camAB.

**Example 6** Microbial conversion with use of *Escherichia coli* recombinant wherein cytochrome P-450 had been expressed

#### (1) Production of carbomycin A

**[0070]** Glycerol culture, in an amount of 10  $\mu$ l, of *Escherichia coli* BL21(DE3) strain which had been transformed with pCBM-camAB among the plasmids as obtained in the above-mentioned Example 4 was added to 2 ml of LB medium to which 50  $\mu$ g/ml (final concentration) of ampicillin had been added, and the resultant mixture was subjected to shake culture at 28°C for 16 hours at 220 rpm. Thus obtained culture liquid in an amount of 250  $\mu$ l was added to 25 ml of NZCYM medium to which 50  $\mu$ g/ml of ampicillin had been added, and the resultant mixture was subjected to shake culture at 37°C for 2.5 hours. Then, 25  $\mu$ l of 100 mM IPTG and 25  $\mu$ l of 80 mg/ml  $\delta$ -aminolevulinic acid were added in order, and the resultant mixture was subjected to shake culture at 22°C at 120 rpm for 16 hours. Cells were recovered by centrifugation from the resultant culture liquid, and were then washed once with conversion buffer-2 (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM EDTA, 0.2 mM DTT, 10 % glycerol, [pH 7.3]). Subsequently, the cells were suspended in 3 ml of said buffer to give a suspension of static cells. To 600  $\mu$ l of this suspension of static cells, 3  $\mu$ l of 100 mg/ml methanol solution of carbomycin B was added, and the resultant mixture was incubated at 28°C for five hours with shaking (220 rpm). Later, to thus obtained reaction liquid, there was added 100  $\mu$ l of 50 % K<sub>2</sub>HPO<sub>4</sub> (pH 8.5) and 100  $\mu$ l of ethyl acetate, and the resultant mixture was subjected to vortex, and then to centrifugation for five minutes at 16,000 rpm with an Eppendorf centrifugator. A TLC plate was spotted with 10  $\mu$ l of so obtained ethyl acetate phase, and was then subjected to development with a developer (ethyl acetate : diethylamine = 100:2). Subsequently, this plate was sprayed with 10 % sulfuric acid, and heated at 100°C for 10 minutes. Spots on which color had come out were analyzed for coloring intensity with a dual-wavelength chromatoscanner CS-930 (manufactured by Shimadzu Seisakusho) at a wavelength of 600 nm, and, thus, there was evaluated the amount of carbomycin A (RF value in TLC: 0.64) which had been formed by the epoxidation of substrate carbomycin B (RF value in TLC: 0.71). As a result, it was confirmed that carbomycin A had been formed with a yield of 90  $\mu$ g/ml. Then, substrate conversion reaction was conducted with use of a control strain BL21(DE3) (pET11a) under the same condition as stated above. As a result of analysis, no formation of carbomycin A was detected.

#### (2) De-ethylation of 7-ethoxycoumarin

**[0071]** Glycerol culture, in an amount of 10  $\mu$ l, of *Escherichia coli* BL21(DE3) strain which had been transformed with pSC154A1-camAB among the plasmids as obtained in the above-mentioned Example 5 was added to 2 ml of LB medium to which 50  $\mu$ g/ml (final concentration) of ampicillin had been added, and the resultant mixture was subjected to shake culture at 28°C for 16 hours at 220 rpm. Thus obtained culture liquid in an amount of 250  $\mu$ l was added to 25 ml of NZCYM medium to which 50  $\mu$ g/ml of ampicillin had been added, and the resultant mixture was subjected to shake culture at 37°C for 2.5 hours. Then, 25  $\mu$ l of 100 mM IPTG and 25  $\mu$ l of 80 mg/ml  $\delta$ -aminolevulinic acid were added in order, and the resultant mixture was subjected to shake culture at 22°C at 120 rpm for 16 hours. Cells were recovered by centrifugation from the resultant culture liquid, and were then washed once with conversion buffer-2 (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM EDTA, 0.2 mM DTT, 10 % glycerol, [pH 7.3]). Subsequently, the cells were suspended in 6 ml of said buffer to give a suspension of static cells. To 1 ml of this suspension of static cells, 5  $\mu$ l of 50 mM DMSO solution of 7-ethoxycoumarin was added, and the resultant mixture was incubated at 28°C for five hours with shaking (220 rpm). Later, to thus obtained reaction liquid, there was added 200  $\mu$ l of ethyl acetate, and the resultant mixture was subjected to vortex, and then to centrifugation for five minutes at 16,000 rpm with an Eppendorf centrifugator. There was taken out 100  $\mu$ l of so obtained ethyl acetate phase, which was then evaporated to dryness in vacuum. The resultant dried pellet was dissolved in 1 ml of 100 mM potassium phosphate buffer (pH 7.4). Thus obtained solution was 80-times diluted, and was then measured for fluorescence (wavelength: 460 nm) with F-2000 spectrophotofluorometer (manufactured by Hitachi Science Systems, Co.) at an excitation wave length of 380 nm for the purpose of evaluation of the amount of 7-hydroxycoumarin which had been formed by de-ethylation of substrate 7-ethoxycoumarin. As a result, fluorescence intensity was 2770, and, thus, the formation of 7-hydroxycoumarin was confirmed. Then, substrate conversion reaction was conducted with use of a control strain BL21(DE3) (pET11a) under the same condition as stated above. As a result of analysis, fluorescence intensity was three or less.

## (3) Dehydrogenation of 13-dihydrodaunomycin

[0072] Glycerol culture, in an amount of 10  $\mu$ l, of *Escherichia coli* BL21(DE3) strain which had been transformed by pDoxA1-camAB among the plasmids as obtained in the above-mentioned Example 5 was added to 2 ml of LB medium to which 50  $\mu$ g/ml (final concentration) of ampicillin had been added, and the resultant mixture was subjected to shake culture at 28°C for 16 hours at 220 rpm. Thus obtained culture liquid in an amount of 250  $\mu$ l was added to 25 ml of NZCYM medium to which 50  $\mu$ g/ml of ampicillin had been added, and the resultant mixture was subjected to shake culture at 37°C for 2.5 hours. Then, 25  $\mu$ l of 100 mM IPTG and 25  $\mu$ l of 80 mg/ml  $\delta$ -aminolevulinic acid were added in order, and the resultant mixture was subjected to shake culture at 22°C at 120 rpm for 24 hours. Cells were recovered by centrifugation from the resultant culture liquid, and were then washed once with conversion buffer-2 (50 mM  $\text{NaH}_2\text{PO}_4$ , 1 mM EDTA, 0.2 mM DTT, 10 % glycerol, [pH 7.3]). Subsequently, the cells were suspended in 4 ml of said buffer to give a suspension of static cells. To 1 ml of this suspension of static cells, 10  $\mu$ l of 10 mg/ml methanol solution of 13-dihydrodaunomycin was added, and the resultant mixture was incubated at 28°C for 24 hours with shaking (220 rpm). Later, to 400  $\mu$ l of thus obtained reaction liquid, there was added 1.2 ml of acetone, and the resultant mixture was subjected to vortex, and was then extracted with 300  $\mu$ l of chloroform. Thus obtained extract was evaporated to dryness in vacuum, and was then dissolved in 500  $\mu$ l of 0.3 M hydrochloric acid, and thus obtained solution was heated at 80°C for 30 minutes. This solution was extracted with 100  $\mu$ l of chloroform, and thus obtained extract was evaporated to dryness in vacuum. The resultant dried pellet was dissolved in 100  $\mu$ l of methanol, and the resultant solution was subjected to HPLC under the following condition, and, thus, there was detected daunomycin which had been formed by the dehydrogenation of substrate 13-dihydrodaunomycin.

(Analytical condition of HPLC)

## [0073]

Analytical apparatus	Shimadzu LC10 Chromatopac (manufactured by Shimadzu Seisakusho)	
Column	ZORBAX TMS (5 $\mu$ ) 4.6 mm $\times$ 250 mm I.D.	
Mobile phase	To a mixture of water/acetonitrile/methanol/phosphoric acid = 540:290:170:2 (volume ratio), 1.0 g of sodium lauryl sulfate was added and dissolved, and, to the resultant mixture, 2N NaOH was added for the adjustment of pH to 3.6.	
Flow rate	1.5 ml/minute	
Wavelength for detection	254 nm	
Injection content	20 $\mu$ l	
Column temperature	40°C	
Analysis time	20 minutes	
Retention time	13-dihydrodaunomycin	4.8 minutes
	daunomycin	5.9 minutes

[0074] Analysis detected 3.7  $\mu$ g/ml of daunomycin. Then, substrate conversion reaction was conducted with use of a control strain BL21(DE3) (pET11a) under the same condition as stated above. As a result of analysis, no formation of daunomycin was detected.

Industrial applicability

[0075] In accordance with this invention, single oxygen atom insertional reaction of organic compound as a substrate can efficiently be conducted with use of a recombinant which has been constructed by use of actinomycete cytochrome P-450 gene and *Escherichia coli* as a host.

[0076] This invention also provides a gene library suitable as an objective of high throughput screening or other simple and rapid enzymatic assay screening for the screening of industrially important and desired actinomycete P-450 enzymes.

<110> MERCIAN CORPORATION

<120> EXPRESSION SYSTEM OF ACTINOMYCETE-ORIGIN CYTOCHROME  
P-450 IN ESCHERICHIA COLI

<130> 14890EP

<140> 03 723 103.2

<141> 2003-04-11

<150> JP2002-110311

<151> 2002-04-12

<160> 32

<170> PatentIn Ver. 2.1

<210> 1

<211> 2696

<212> DNA

<213> Microtetraspora recticatena IF014525

<220>

<221> CDS

<222> (313)..(1536)

<220>

<221> CDS

<222> (1547)..(1741)

<400> 1

tgcgctccac cgcgttcttc gacggccgag gggccaccca ctccgtcatc gtcctgctcg 60

cctggctcac gctcggtgtc gtgctgtgcg tggccagcgg cctgcgcgcg cgccgtgccg 120

ccaccgtcgc cgcgggactt gtgaggacgc cggcagcacc ggcccctacg acgttcgcaa 180

ccccgagagg ctgaccgcat cgctgcccac gaagcggcgg cgcgacagcc acctgaccag 240

gcaccgcttc tggcctcacc atccgaacag cccagaacga attcagccag atctctcacc 300

aggaggttat tc atg acg aag aac gtc gcc gac gaa ctg gcc ggc ctg gaa 351

Met Thr Lys Asn Val Ala Asp Glu Leu Ala Gly Leu Glu  
1 5 10

ctg ccg gtc gag cgg ggc tgc ccg ttc gcc ccg ccc gcc gcc tac gag 399

Leu Pro Val Glu Arg Gly Cys Pro Phe Ala Pro Pro Ala Ala Tyr Glu  
15 20 25

cgg ctg cgc gag cgg gcg ccg atc aac aag gtc cgc ctg acc agc ggc 447

Arg Leu Arg Glu Arg Ala Pro Ile Asn Lys Val Arg Leu Thr Ser Gly  
30 35 40 45

ggc cag gcg tgg tgg gtg tcc ggg cac gag gag gcc cgt gcc gtc ctc 495

Gly Gln Ala Trp Val Ser Gly His Glu Glu Ala Arg Ala Val Leu  
50 55 60

gcc gac ggc cgc ttc tcc tcc gac aag cgc aag gac ggc ttc ccg ctc 543

Ala Asp Gly Arg Phe Ser Ser Asp Lys Arg Lys Asp Gly Phe Pro Leu  
65 70 75

EP 1 500 704 A1

5	ttc acc ctc gac gcg gcg acc ctg cag cag ctc cgc agc cag ccg ccg Phe Thr Leu Asp Ala Ala Thr Leu Gln Gln Leu Arg Ser Gln Pro Pro 80 85 90	591
10	ttg atg ctc ggc atg gac ggc gcg gaa cac tcc gcg gcc cgc cgt ccg Leu Met Leu Gly Met Asp Gly Ala Glu His Ser Ala Ala Arg Arg Pro 95 100 105	639
15	gtg atc ggc gag ttc acc gtg aag cgg ctg gcc gcg ctg cgc ccg agg Val Ile Gly Glu Phe Thr Val Lys Arg Leu Ala Ala Leu Arg Pro Arg 110 115 120 125	687
20	atc cag gac atc gtc gac cac ttc atc gac gac atg ctc gcc acc gac Ile Gln Asp Ile Val Asp His Phe Ile Asp Asp Met Leu Ala Thr Asp 130 135 140	735
25	cag cgc ccg gtc gac ctg gtg cag gcg ctg tcc ctg ccg gtg ccc tca Gln Arg Pro Val Asp Leu Val Gln Ala Leu Ser Leu Pro Val Pro Ser 145 150 155	783
30	ctg gtg atc tgc gaa ctg ctc ggc gtc ccc tac acc gac cac gac ttc Leu Val Ile Cys Glu Leu Leu Gly Val Pro Tyr Thr Asp His Asp Phe 160 165 170	831
35	ttc cag agc cgc acc acc atg atg gtg agc cgg acc tcg atg gaa gac Phe Gln Ser Arg Thr Thr Met Met Val Ser Arg Thr Ser Met Glu Asp 175 180 185	879
40	cgc cgg cga gcc ttc gcc gaa ctg cgc gcc tac atc gac gac ctg atc Arg Arg Arg Ala Phe Ala Glu Leu Arg Ala Tyr Ile Asp Asp Leu Ile 190 195 200 205	927
45	acc cgc aag gag tcc gaa ccc ggc gac gac ctg ttc agc cga cag atc Thr Arg Lys Glu Ser Glu Pro Gly Asp Asp Leu Phe Ser Arg Gln Ile 210 215 220	975
50	gcc cgg caa cgc cag gag ggc acc ctc gac cat gcg gcc ctg gtg agc Ala Arg Gln Arg Gln Glu Gly Thr Leu Asp His Ala Gly Leu Val Ser 225 230 235	1023
55	ctc gcc ttc ctg ctg ctg acc gcc gga cac gag acc acc gcg aac atg Leu Ala Phe Leu Leu Leu Thr Ala Gly His Glu Thr Thr Ala Asn Met 240 245 250	1071
60	atc tcg ctc ggc gtg gtc ggg ctg ctc tct cac ccg gag caa ctg acc Ile Ser Leu Gly Val Val Gly Leu Leu Ser His Pro Glu Gln Leu Thr 255 260 265	1119
65	gtg gtc aag gcc aac ccg ggc aga acg ccc atg gcc gtg gag gaa ctg Val Val Lys Ala Asn Pro Gly Arg Thr Pro Met Ala Val Glu Glu Leu 270 275 280 285	1167
70	ctg cgc tac ttc acc atc gcc gac ggg gtc acc tcc cgg ctg gcc acc Leu Arg Tyr Phe Thr Ile Ala Asp Gly Val Thr Ser Arg Leu Ala Thr 290 295 300	1215
75	gaa gac gtg gag atc ggc ggg gtg agc atc aag gcc ggt gag ggc gtc Glu Asp Val Glu Ile Gly Gly Val Ser Ile Lys Ala Gly Glu Gly Val 305 310 315	1263
80	atc gtc tcg atg ctg tcg gcc aac tgg gac ccg gcg gtg ttc aag gac Ile Val Ser Met Leu Ser Ala Asn Trp Asp Pro Ala Val Phe Lys Asp 320 325 330	1311

**EP 1 500 704 A1**

55

EP 1 500 704 A1

ttacctcggc tcggcggtcg cggaccacct ggacgaggcc ggacaccaca tcgtcgaact 2581  
gaccgcgcc accgacgacc gcccgagaa cgggcgccaa gcagccgtgt cggcgacctt 2641  
5 gaccgatccc gcgttcgctt aaccccgggc ggtgaccccc cgacattgac cgccc 2696

<210> 2  
<211> 407  
10 <212> PRT  
<213> Microtetrastora recticatena IF014525

<400> 2  
Met Thr Lys Asn Val Ala Asp Glu Leu Ala Gly Leu Glu Leu Pro Val  
1 5 10 15  
15 Glu Arg Gly Cys Pro Phe Ala Pro Pro Ala Ala Tyr Glu Arg Leu Arg  
20 25 30  
Glu Arg Ala Pro Ile Asn Lys Val Arg Leu Thr Ser Gly Gly Gln Ala  
35 40 45  
Trp Trp Val Ser Gly His Glu Glu Ala Arg Ala Val Leu Ala Asp Gly  
50 55 60  
20 Arg Phe Ser Ser Asp Lys Arg Lys Asp Gly Phe Pro Leu Phe Thr Leu  
65 70 75 80  
Asp Ala Ala Thr Leu Gln Gln Leu Arg Ser Gln Pro Pro Leu Met Leu  
85 90 95  
25 Gly Met Asp Gly Ala Glu His Ser Ala Ala Arg Arg Pro Val Ile Gly  
100 105 110  
Glu Phe Thr Val Lys Arg Leu Ala Leu Arg Pro Arg Ile Gln Asp  
115 120 125  
Ile Val Asp His Phe Ile Asp Asp Met Leu Ala Thr Asp Gln Arg Pro  
130 135 140  
30 Val Asp Leu Val Gln Ala Leu Ser Leu Pro Val Pro Ser Leu Val Ile  
145 150 155 160  
Cys Glu Leu Leu Gly Val Pro Tyr Thr Asp His Asp Phe Phe Gln Ser  
165 170 175  
Arg Thr Thr Met Met Val Ser Arg Thr Ser Met Glu Asp Arg Arg Arg  
180 185 190  
35 Ala Phe Ala Glu Leu Arg Ala Tyr Ile Asp Asp Leu Ile Thr Arg Lys  
195 200 205  
Glu Ser Glu Pro Gly Asp Asp Leu Phe Ser Arg Gln Ile Ala Arg Gln  
210 215 220  
Arg Gln Glu Gly Thr Leu Asp His Ala Gly Leu Val Ser Leu Ala Phe  
225 230 235 240  
40 Leu Leu Leu Thr Ala Gly His Glu Thr Thr Ala Asn Met Ile Ser Leu  
245 250 255  
Gly Val Val Gly Leu Leu Ser His Pro Glu Gln Leu Thr Val Val Lys  
260 265 270  
Ala Asn Pro Gly Arg Thr Pro Met Ala Val Glu Glu Leu Leu Arg Tyr  
275 280 285  
45 Phe Thr Ile Ala Asp Gly Val Thr Ser Arg Leu Ala Thr Glu Asp Val  
290 295 300  
Glu Ile Gly Gly Val Ser Ile Lys Ala Gly Glu Gly Val Ile Val Ser  
305 310 315 320  
Met Leu Ser Ala Asn Trp Asp Pro Ala Val Phe Lys Asp Pro Ala Val  
325 330 335  
50 Leu Asp Val Glu Arg Gly Ala Arg His Leu Ala Phe Gly Phe Gly  
340 345 350  
Pro His Gln Cys Leu Gly Gln Asn Leu Ala Arg Met Glu Leu Gln Ile  
355 360 365  
Val Phe Asp Thr Leu Phe Arg Arg Ile Pro Ser Leu Arg Leu Ala Val  
370 375 380  
55 Pro Met Glu Asp Val Pro Phe Lys Gly Asp Ser Val Ile Tyr Gly Val  
385 390 395 400

His Glu Leu Pro Val Thr Trp  
405

5 <210> 3  
<211> 65  
<212> PRT  
<213> Microtetraspora recticatena IFO14525

10 <400> 3  
Met Arg Ile Lys Ala Glu Thr Gly Leu Cys Val Gly Ser Gly Gln Cys  
1 5 10 15  
Val Leu Thr Glu Pro Ala Val Phe Asp Gln Asp Asp Asp Gly Ile Val  
20 25 30  
Ala Leu Leu Thr Asp His Pro Asp Asp Gln Ser Ala Ala Gln Val Arg  
15 35 40 45  
His Ala Val Thr Leu Cys Pro Ser Arg Ala Leu Ser Ile Leu Arg Asp  
50 55 60  
Ala  
65

20

<210> 4  
<211> 1992  
<212> DNA  
25 <213> Streptomyces sp.TM-7

<220>  
<221> CDS  
<222> (544)..(1761)

30

<220>  
<221> CDS  
<222> (1782)..(1970)

35

<400> 4  
tcgcggggcc cggcggtgtg gaccgttcgc ggaccagccg ggccaattcg gggtcgtgca 60  
tgacctcggt gagcaggccg cggagtatgt ccgccgtgcg aggcggccaa cctggcgagg 120  
agtcgccgta gcgcggtgat gacatcggtg cgcaggcgcc cgggtgtcggg caggtcggcg 180  
40 tcggacagcc ggtgggcccgc gcaggcgctc acgacgagtt cggcacggcc gggccacctc 240  
cggtagcaggg tggccttgcc ggtacggggc cgtgcggcca cgcgtccat cgtcagtc 300  
ggcgtagtcc gacctcggtc agtttcctcg agggtcgcgg ccaggatggc cctctccagt 360  
45 tcctctctc ggccggcgag ggtttttcga tggtcgcggt cgtccgggtcc ggcgcgtccc 420  
cgtggggttg aggcattgact ccagccatt tgcgagcac ccgttgtgag cgtcgggtgg 480  
gtaagcctag ccttcggtta gagaactgac cgttctttaa gcgtcgagtg catcgaggga 540

50

ccg atg acc gag acc gtt acg acg ccc aca tca ggc gcc ccc gcc ttc 588  
Met Thr Glu Thr Val Thr Thr Pro Thr Ser Gly Ala Pro Ala Phe  
1 5 10 15

55

ccc agt gac cgc acc tgc ccc tac cac ctc ccc gac cgg tac aac gac 636  
Pro Ser Asp Arg Thr Cys Pro Tyr His Leu Pro Asp Arg Tyr Asn Asp  
20 25 30

EP 1 500 704 A1

	ctc cgg gac cgg gag ggt tgc ctg cag cgg gtc acc ctc tac gac ggc	684
	Leu Arg Asp Arg Glu Gly Ser Leu Gln Arg Val Thr Leu Tyr Asp Gly	
	35 40 45	
5	cgg cag gca tgg ctg gtg acc ggg tac gac acg gca cgc aag ctg ctg	732
	Arg Gln Ala Trp Leu Val Thr Gly Tyr Asp Thr Ala Arg Lys Leu Leu	
	50 55 60	
10	gcc gac ccc cgg ctc tgc tcc gac cgg aca cac gcc gac ttc ccc gcc	780
	Ala Asp Pro Arg Leu Ser Ser Asp Arg Thr His Ala Asp Phe Pro Ala	
	65 70 75	
	acc tcc ggg cgg gtg gag agc ttc cgg gac cgc cgg ccg gcg ttc atc	828
	Thr Ser Gly Arg Val Glu Ser Phe Arg Asp Arg Arg Pro Ala Phe Ile	
15	80 85 90 95	
	agc ctg gac ccg ccc gag cac ggg ccg aaa cgg cgc cat gac cat cag	876
	Ser Leu Asp Pro Glu His Gly Pro Lys Arg Arg His Asp His Gln	
	100 105 110	
20	gag ttc acc gtc cgg cgc atc aag ggc atg cgg gcc gac gtc gag cag	924
	Glu Phe Thr Val Arg Arg Ile Lys Gly Met Arg Ala Asp Val Glu Gln	
	115 120 125	
	atc gtg cac ggc ttc ctg gac gag atg atc gca ggc ggc ccg ccc gcc	972
	Ile Val His Gly Phe Leu Asp Glu Met Ile Ala Gly Gly Pro Pro Ala	
25	130 135 140	
	gac ctg gtc agc cag ttc gcg ctg ccg gtc ccg tcc ctg gtg atc tgc	1020
	Asp Leu Val Ser Gln Phe Ala Leu Pro Val Pro Ser Leu Val Ile Cys	
	145 150 155	
30	cgt ctg ctc ggt gtg ccc tac gcg gac cac gac ttc ttc cag gac gcc	1068
	Arg Leu Leu Gly Val Pro Tyr Ala Asp His Asp Phe Phe Gln Asp Ala	
	160 165 170 175	
	agc gca cgg ctg atc cag tcc ccg gac gcg gcg ggt gcg cgt gcc gcc	1116
	Ser Ala Arg Leu Ile Gln Ser Pro Asp Ala Ala Gly Ala Arg Ala Ala	
35	180 185 190	
	cgg gac gac ctg gag agc tat ctg ggc gct ctg gtg gac agc ctg cga	1164
	Arg Asp Asp Leu Glu Ser Tyr Leu Gly Ala Leu Val Asp Ser Leu Arg	
	195 200 205	
40	ggc gag tcc cgg ccg ggc ctg ctg agc acg ctc gtc agg gag cag ctg	1212
	Gly Glu Ser Arg Pro Gly Leu Leu Ser Thr Leu Val Arg Glu Gln Leu	
	210 215 220	
	gag aag ggc gcg atc gac cgg gag gag ctg gtg tgc acg gcg atc ctg	1260
	Glu Lys Gly Ala Ile Asp Arg Glu Glu Leu Val Ser Thr Ala Ile Leu	
45	225 230 235	
	ctg ctg gtc gcc gga cac gag gcg acg gcg tgc atg acg tgc ctc agc	1308
	Leu Leu Val Ala Gly His Glu Ala Thr Ala Ser Met Thr Ser Leu Ser	
50	240 245 250 255	
	gtc atc acc ctc ctc gaa cat ccc gac cag cac gcc gcg ttg cgc gcc	1356
	Val Ile Thr Leu Leu Glu His Pro Asp Gln His Ala Ala Leu Arg Ala	
	260 265 270	
55	gat ccg tgc ctg gtg ccc ggc gcg gtg gag gag ctg ctg cgc tat ctg	1404
	Asp Pro Ser Leu Val Pro Gly Ala Val Glu Glu Leu Leu Arg Tyr Leu	
	275 280 285	

**EP 1 500 704 A1**

gcc atc gcc gac atc gcc ggc ggg cgg atc gcg acg gcg gac atc gag 1452  
Ala Ile Ala Asp Ile Ala Gly Gly Arg Ile Ala Thr Ala Asp Ile Glu  
290 295 300

atc gac ggg cag cgc atc cgg gcg ggg gag ggg gtc atc gtc acc aac 1500  
Ile Asp Gly Gln Arg Ile Arg Ala Gly Glu Gly Val Ile Val Thr Asn  
305 310 315

tcg atc gcc aac cgc gac ggc tcc gtc ttc gcc gac ccg gac gcc ttc 1548  
Ser Ile Ala Asn Arg Asp Gly Ser Val Phe Ala Asp Pro Asp Ala Phe  
320 325 330 335

gac gtg cgg cgc gag gcc cgc cac cac ctg gcg ttc ggc tac ggg gtg 1596  
Asp Val Arg Arg Glu Ala Arg His His Leu Ala Phe Gly Tyr Gly Val  
340 345 350

cat cag tgc ctc ggc cag aac ctg gcc cgc ctc gaa ctg gag gtc atc 1644  
His Gln Cys Leu Gly Gln Asn Leu Ala Arg Leu Glu Leu Glu Val Ile  
355 360 365

ctc acg gcg ctg ttc gag cgg ctg ccc ggt ctg cgg ctg gcg gtg ccg 1692  
Leu Thr Ala Leu Phe Glu Arg Leu Pro Gly Leu Arg Leu Ala Val Pro  
370 375 380

gtg gac cgg ctg acc ctg cgc ccg ggc acg acg atc cag ggc gtg aac 1740  
Val Asp Arg Leu Thr Leu Arg Pro Gly Thr Thr Ile Gln Gly Val Asn  
385 390 395

gaa ctc ccg gtc acc tgg tga ccgcggcgaa aggagcagcc atg cgt gtg acg 1793  
Glu Leu Pro Val Thr Trp Met Arg Val Thr  
400 405 410

gcc gac cgg gag gtc tgc gtg gga gcg ggc ctg tgc gcc ttg acg gcg 1841  
Ala Asp Arg Glu Val Cys Val Gly Ala Gly Leu Cys Ala Leu Thr Ala  
415 420 425

ccg gag gtc ttc gac cag gac gac gac ggt gtg gtg acg gtg ctg gcc 1889  
Pro Glu Val Phe Asp Gln Asp Asp Asp Gly Val Val Thr Val Leu Ala  
430 435 440

gcg gaa ccc ggc gag gcc ggc cgt gcg gcg gca ctc gaa gcc ggc gtg 1937  
Ala Glu Pro Gly Glu Ala Gly Arg Ala Ala Ala Leu Glu Ala Gly Val  
445 450 455

ctg tgc ccg tcc gcc gcg gta cgc gtc gtc gag tagggggccgt gcgggggccgt 1990  
Leu Cys Pro Ser Gly Ala Val Arg Val Val Glu  
460 465

ga 1992

<210> 5

<211> 405

<212> PRT

<213> Streptomyces sp.TM-7

<400> 5

Met Thr Glu Thr Val Thr Thr Pro Thr Ser Gly Ala Pro Ala Phe Pro  
1 5 10 15  
Ser Asp Arg Thr Cys Pro Tyr His Leu Pro Asp Arg Tyr Asn Asp Leu  
20 25 30

EP 1 500 704 A1

Arg Asp Arg Glu Gly Ser Leu Gln Arg Val Thr Leu Tyr Asp Gly Arg  
35 40 45  
Gln Ala Trp Leu Val Thr Gly Tyr Asp Thr Ala Arg Lys Leu Leu Ala  
50 55 60  
Asp Pro Arg Leu Ser Ser Asp Arg Thr His Ala Asp Phe Pro Ala Thr  
65 70 75 80  
Ser Gly Arg Val Glu Ser Phe Arg Asp Arg Arg Pro Ala Phe Ile Ser  
85 90 95  
Leu Asp Pro Pro Glu His Gly Pro Lys Arg Arg His Asp His Gln Glu  
100 105 110  
Phe Thr Val Arg Arg Ile Lys Gly Met Arg Ala Asp Val Glu Gln Ile  
115 120 125  
Val His Gly Phe Leu Asp Glu Met Ile Ala Gly Gly Pro Pro Ala Asp  
130 135 140  
Leu Val Ser Gln Phe Ala Leu Pro Val Pro Ser Leu Val Ile Cys Arg  
145 150 155 160  
Leu Leu Gly Val Pro Tyr Ala Asp His Asp Phe Phe Gln Asp Ala Ser  
165 170 175  
Ala Arg Leu Ile Gln Ser Pro Asp Ala Ala Gly Ala Arg Ala Ala Arg  
180 185 190  
Asp Asp Leu Glu Ser Tyr Leu Gly Ala Leu Val Asp Ser Leu Arg Gly  
195 200 205  
Glu Ser Arg Pro Gly Leu Leu Ser Thr Leu Val Arg Glu Gln Leu Glu  
210 215 220  
Lys Gly Ala Ile Asp Arg Glu Glu Leu Val Ser Thr Ala Ile Leu Leu  
225 230 235 240  
Leu Val Ala Gly His Glu Ala Thr Ala Ser Met Thr Ser Leu Ser Val  
245 250 255  
Ile Thr Leu Leu Glu His Pro Asp Gln His Ala Ala Leu Arg Ala Asp  
260 265 270  
Pro Ser Leu Val Pro Gly Ala Val Glu Glu Leu Leu Arg Tyr Leu Ala  
275 280 285  
Ile Ala Asp Ile Ala Gly Gly Arg Ile Ala Thr Ala Asp Ile Glu Ile  
290 295 300  
Asp Gly Gln Arg Ile Arg Ala Gly Glu Gly Val Ile Val Thr Asn Ser  
305 310 315 320  
Ile Ala Asn Arg Asp Gly Ser Val Phe Ala Asp Pro Asp Ala Phe Asp  
325 330 335  
Val Arg Arg Glu Ala Arg His His Leu Ala Phe Gly Tyr Gly Val His  
340 345 350  
Gln Cys Leu Gly Gln Asn Leu Ala Arg Leu Glu Leu Glu Val Ile Leu  
355 360 365  
Thr Ala Leu Phe Glu Arg Leu Pro Gly Leu Arg Leu Ala Val Pro Val  
370 375 380  
Asp Arg Leu Thr Leu Arg Pro Gly Thr Thr Ile Gln Gly Val Asn Glu  
385 390 395 400  
Leu Pro Val Thr Trp  
405

<210> 6  
<211> 63  
<212> PRT  
<213> Streptomyces sp.TM-7

<400> 6  
Met Arg Val Thr Ala Asp Arg Glu Val Cys Val Gly Ala Gly Leu Cys  
1 5 10 15  
Ala Leu Thr Ala Pro Glu Val Phe Asp Gln Asp Asp Asp Gly Val Val  
20 25 30  
Thr Val Leu Ala Ala Glu Pro Gly Glu Ala Gly Arg Ala Ala Ala Leu  
35 40 45

# EP 1 500 704 A1

Glu Ala Gly Val Leu Cys Pro Ser Gly Ala Val Arg Val Val Glu  
50 55 60

5

<210> 7  
<211> 45  
<212> DNA  
<213> Artificial Sequence

10

<220>  
<223> Description of Artificial Sequence:FDR1-1F Primer

15

<400> 7  
gccatatgac tagtgcgccct cacagactgg aacgggaatc tcatg 45

20

<210> 8  
<211> 38  
<212> DNA  
<213> Artificial Sequence

25

<220>  
<223> Description of Artificial Sequence:FDR1-2R Primer  
<400> 8  
gcgaattctg tcggtcaggc ctggtctccc gtcggccg 38

30

<210> 9  
<211> 1438  
<212> DNA  
<213> Streptomyces coelicolor A3(2)

35

<220>  
<221> CDS  
<222> (117)..(1376)

40

<400> 9  
gatcacgggg gccgggtagg cccgtgccac ggtgtcaciaa cgcgtgtcgt cgcccgggtct 60  
gaaggatgac cggaccactc ggtccgtgtg cgcctcacag actggaacgg gaatct atg 119  
Met 1

45

ccg cgt gcg aag acg ttc gtg atc gtc ggg ggc ggc ctg gcc gcc ggc 167  
Pro Arg Ala Lys Thr Phe Val Ile Val Gly Gly Gly Leu Ala Ala Gly  
5 10 15

50

aag gcc gcg gag gaa ctg cgc gag cac ggc cac gac ggg ccg ctt ctc 215  
Lys Ala Ala Glu Glu Leu Arg Glu His Gly His Asp Gly Pro Leu Leu  
20 25 30

gtg atc ggg gac gag cgg gaa cga ccg tac atc cgg ccg ccg ctg tcc 263  
Val Ile Gly Asp Glu Arg Glu Arg Pro Tyr Ile Arg Pro Pro Leu Ser  
35 40 45

55

aag ggg tac ctg ctg ggc aag gag gac cgc gag tcc atc cac gtg cac 311  
Lys Gly Tyr Leu Leu Gly Lys Glu Asp Arg Glu Ser Ile His Val His  
50 55 60 65

EP 1 500 704 A1

	ccc gag agc tgg tac cgg gag cac gac gtc gat ctg ctc ctc ggc acg	359
	Pro Glu Ser Trp Tyr Arg Glu His Asp Val Asp Leu Leu Leu Gly Thr	
	70 75 80	
5	agc gtg acg tcc gtc gac gcg cgt ggc cgg gcg gtg acg ctg gac gac	407
	Ser Val Thr Ser Val Asp Ala Arg Gly Arg Ala Val Thr Leu Asp Asp	
	85 90 95	
10	ggc cgt cgc gtg ccc tac gcc ggt ctg ctg ctg gcc acc ggt tcc tcg	455
	Gly Arg Arg Val Pro Tyr Ala Gly Leu Leu Leu Ala Thr Gly Ser Ser	
	100 105 110	
	ccg cgc cgc ctg tcc gtg ccg ggc gcg gac ctg gag ggc gtg ctg tac	503
	Pro Arg Arg Leu Ser Val Pro Gly Ala Asp Leu Glu Gly Val Leu Tyr	
	115 120 125	
15	ctg cgg cgc gtg ggc gac agc gag cgc ctc aag gag gcg ttc acc gaa	551
	Leu Arg Arg Val Gly Asp Ser Glu Arg Leu Lys Glu Ala Phe Thr Glu	
	130 135 140 145	
20	gga gcc cgg atc gtg gtg gtc ggc ggc ggc tgg atc ggg ctg gag acg	599
	Gly Ala Arg Ile Val Val Val Gly Gly Gly Trp Ile Gly Leu Glu Thr	
	150 155 160	
	gcg gcg gcg gcc cgg gcg gcc ggc gcg gag gtg acc gtg ctg gag cgc	647
	Ala Ala Ala Ala Arg Ala Ala Gly Ala Glu Val Thr Val Leu Glu Arg	
25	165 170 175	
	ggt gag ctg ccc ctg ctg aag gtc ctg ggc cgc gag gcg gcc gag gtc	695
	Gly Glu Leu Pro Leu Leu Lys Val Leu Gly Arg Glu Ala Ala Glu Val	
	180 185 190	
30	ttc gcc ggt ctg cac cgg gac cac ggt gtg gac ctg cgt ccc cat gcc	743
	Phe Ala Gly Leu His Arg Asp His Gly Val Asp Leu Arg Pro His Ala	
	195 200 205	
	cgg atc gag gcc gtc acc ggc acc ggg ggc cgc gtc gac ggg gtc cgg	791
	Arg Ile Glu Ala Val Thr Gly Thr Gly Gly Arg Val Asp Gly Val Arg	
35	210 215 220 225	
	ctc gcc gac ggc acc cac ctg ccc gcg gac gcc gtg gtc gtg ggg gtg	839
	Leu Ala Asp Gly Thr His Leu Pro Ala Asp Ala Val Val Val Gly Val	
	230 235 240	
40	ggc atc acg ccc aac gtc cgc ctg gcc gag gag gcg ggc ctc gac gtg	887
	Gly Ile Thr Pro Asn Val Arg Leu Ala Glu Glu Ala Gly Leu Asp Val	
	245 250 255	
	cgc aac ggc atc gtg acg gac gcc cgt ctg cgg acc tcc gcc gcc ggg	935
	Arg Asn Gly Ile Val Thr Asp Ala Arg Leu Arg Thr Ser Ala Ala Gly	
45	260 265 270	
	gtc cac gcc gcc ggt gac gtc gcc aac gcc tac cac ccc cgg ctc ggc	983
	Val His Ala Ala Gly Asp Val Ala Asn Ala Tyr His Pro Arg Leu Gly	
	275 280 285	
50	cgg cac ctg cgc gtg gag cac tgg gcc aac gcg ctg cac cag ccc cgt	1031
	Arg His Leu Arg Val His Trp Ala Asn Ala Leu His Gln Pro Arg	
	290 295 300 305	
55	acc gcc gcg ctg agc atg ctc ggc cag gac gcg gtg tac gac cgg ctg	1079
	Thr Ala Ala Leu Ser Met Leu Gly Gln Asp Ala Val Tyr Asp Arg Leu	
	310 315 320	



EP 1 500 704 A1

Tyr Leu Arg Arg Val Gly Asp Ser Glu Arg Leu Lys Glu Ala Phe Thr  
 130 135 140  
 5 Glu Gly Ala Arg Ile Val Val Val Gly Gly Gly Trp Ile Gly Leu Glu  
 145 150 155 160  
 Thr Ala Ala Ala Ala Arg Ala Ala Gly Ala Glu Val Thr Val Leu Glu  
 165 170 175  
 10 Arg Gly Glu Leu Pro Leu Leu Lys Val Leu Gly Arg Glu Ala Ala Glu  
 180 185 190  
 Val Phe Ala Gly Leu His Arg Asp His Gly Val Asp Leu Arg Pro His  
 195 200 205  
 15 Ala Arg Ile Glu Ala Val Thr Gly Thr Gly Gly Arg Val Asp Gly Val  
 210 215 220  
 Arg Leu Ala Asp Gly Thr His Leu Pro Ala Asp Ala Val Val Val Gly  
 225 230 235 240  
 20 Val Gly Ile Thr Pro Asn Val Arg Leu Ala Glu Glu Ala Gly Leu Asp  
 245 250 255  
 Val Arg Asn Gly Ile Val Thr Asp Ala Arg Leu Arg Thr Ser Ala Ala  
 260 265 270  
 25 Gly Val His Ala Ala Gly Asp Val Ala Asn Ala Tyr His Pro Arg Leu  
 275 280 285  
 Gly Arg His Leu Arg Val Glu His Trp Ala Asn Ala Leu His Gln Pro  
 290 295 300  
 30 Arg Thr Ala Ala Leu Ser Met Leu Gly Gln Asp Ala Val Tyr Asp Arg  
 305 310 315 320  
 Leu Pro Tyr Phe Tyr Thr Asp Gln Tyr Asp Leu Gly Met Glu Tyr Thr  
 325 330 335  
 35 Gly Tyr Ala Glu Pro Gly Gly Tyr Asp Arg Val Val Phe Arg Gly Ser  
 340 345 350  
 Arg Glu Glu Arg Arg Phe Leu Ala Phe Trp Met Ser Gly Asp Arg Val  
 355 360 365  
 Leu Ala Gly Met Ser Val Asn Leu Trp Asp Val Ile Gly Thr Ile Arg  
 370 375 380  
 40 Ala Leu Ile Glu Ser Gly Ala Glu Thr Asp Asp Ala Ala Leu Ala Asp  
 385 390 395 400  
 Pro Ser Val Pro Leu Glu Ser Leu Leu Pro Pro His Ala Arg Pro Thr  
 405 410 415  
 50 Gly Asp Gln Ala  
 420

<210> 11  
 <211> 43  
 <212> DNA  
 <213> Artificial Sequence

# EP 1 500 704 A1

<220>

<223> Description of Artificial Sequence:FDR2-3F Primer

<400> 11

cgactagtga cgaggaggca gacaaatggt cgacgcggat cag 43

<210> 12

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:FDR2-4R Primer

<400> 12

cgggatccga caactatgcg acgaggcttt cgaggg 36

<210> 13

<211> 1319

<212> DNA

<213> Streptomyces coelicolor A3(2)

<220>

<221> CDS

<222> (34)..(1296)

<400> 13

cacgtggcgg caccctgacg aggaggcaga caa gtg gtc gac gcg gat cag aca 54  
Val Val Asp Ala Asp Gln Thr  
1 5

ttc gtc atc gtc gga ggc ggc ctg gcg ggc gcg aaa gcg gcc gag acg 102  
Phe Val Ile Val Gly Gly Gly Leu Ala Gly Ala Lys Ala Ala Glu Thr  
10 15 20

ctc cgc acg gag ggc ttc acc ggc cgg gtg atc ctc gtc tgc gac gaa 150  
Leu Arg Thr Glu Gly Phe Thr Gly Arg Val Ile Leu Val Cys Asp Glu  
25 30 35

cgc gac cac ccc tac gag cgc ccg ccg ctg tcc aag ggc tac ctc ctg 198  
Arg Asp His Pro Tyr Glu Arg Pro Pro Leu Ser Lys Gly Tyr Leu Leu  
40 45 50 55

ggc aag gag gag cgc gac agc gtc ttc gtg cac gag ccc gcc tgg tac 246  
Gly Lys Glu Glu Arg Asp Ser Val Phe Val His Glu Pro Ala Trp Tyr  
60 65 70

gcc cgg cac gac atc gag ctg cac ctc ggc cag acc gtc gtc gcg atc 294  
Ala Arg His Asp Ile Glu Leu His Leu Gly Gln Thr Val Val Ala Ile  
75 80 85

gac cgc gcc gcc aag acc gtc cac tac ggc gac gac ggc acc cac gtc 342  
Asp Arg Ala Ala Lys Thr Val His Tyr Gly Asp Asp Gly Thr His Val  
90 95 100

agc tac gac aag ctg ctc atc gcg acc ggc gcc gag ccc cgc cgc ctg 390  
Ser Tyr Asp Lys Leu Leu Ile Ala Thr Gly Ala Glu Pro Arg Arg Leu  
105 110 115

EP 1 500 704 A1

	gac gtc ccc ggc acc ggc ctc gcg ggc gtc cac cac ctg cgc cgc ctg	438
	Asp Val Pro Gly Thr Gly Leu Ala Gly Val His His Leu Arg Arg Leu	
	120 125 130 135	
5	gcg cac gcc gag cgc ctc aag ggc gtc ctc gcc acc ctc ggc cgg gac	486
	Ala His Ala Glu Arg Leu Lys Gly Val Leu Ala Thr Leu Gly Arg Asp	
	140 145 150	
10	aac gga cac ctg gtg atc gcc ggc gcg ggc tgg atc ggc ctg gag gtc	534
	Asn Gly His Leu Val Ile Ala Gly Ala Gly Trp Ile Gly Leu Glu Val	
	155 160 165	
15	gcg gcc gcg gcc cgc gag tac ggt gcg gag gtc acc gtc atc gag ccc	582
	Ala Ala Ala Ala Arg Glu Tyr Gly Ala Glu Val Thr Val Ile Glu Pro	
	170 175 180	
	gcc ccg acc ccg ctg cac ggc gtc ctc ggt ccc gag ctg ggc gcc gtc	630
	Ala Pro Thr Pro Leu His Gly Val Leu Gly Pro Glu Leu Gly Ala Val	
	185 190 195	
20	ttc gcc gag ctg cac gag tcg cgc ggc gtc cgc ttc cgc ttc ggc gtg	678
	Phe Ala Glu Leu His Glu Ser Arg Gly Val Arg Phe Arg Phe Gly Val	
	200 205 210 215	
25	aag ctg acc gag atc gtc ggc cag gac ggt gtg gtg ctg gcc gcc cgc	726
	Lys Leu Thr Glu Ile Val Gly Gln Asp Gly Val Val Leu Ala Ala Arg	
	220 225 230	
	acc gac gac ggc gag gag cac ccc gcg cac gac gtg ctc gcc gcg atc	774
	Thr Asp Asp Gly Glu Glu His Pro Ala His Asp Val Leu Ala Ala Ile	
	235 240 245	
30	ggc gcc gcc ccg cgc acc gcg ctc gcc cag gcg gcc ggg ttg gag atc	822
	Gly Ala Ala Pro Arg Thr Ala Leu Ala Gln Ala Ala Gly Leu Glu Ile	
	250 255 260	
35	gcc gac cgc gcg cac ggc ggc ggc atc gtc gtc gac gac cac ctg cgc	870
	Ala Asp Arg Ala His Gly Gly Ile Val Val Asp Asp His Leu Arg	
	265 270 275	
	acc tcc gac ccc gac atc ttc gcg gcc ggc gac gtg gcc tcc ttc cac	918
	Thr Ser Asp Pro Asp Ile Phe Ala Ala Gly Asp Val Ala Ser Phe His	
	280 285 290 295	
40	cac gcc ctc ttc gac acc agc ctg cgc gtg gag cac tgg gcc aac gcc	966
	His Ala Leu Phe Asp Thr Ser Leu Arg Val Glu His Trp Ala Asn Ala	
	300 305 310	
45	ctg aac ggc ggt ccg gcc gcc gcc cgc gcg atg ctc ggc agg ggc ctc	1014
	Leu Asn Gly Gly Pro Ala Ala Ala Arg Ala Met Leu Gly Arg Gly Leu	
	315 320 325	
	gcc cac gac cgc gtg ccc tac ttc ttc acc gac cag tac gac ctg ggc	1062
	Ala His Asp Arg Val Pro Tyr Phe Phe Thr Asp Gln Tyr Asp Leu Gly	
	330 335 340	
50	atg gag tac tcc ggc tgg gcg ccg gcc ggc tcg tac gac cag gtg gtg	1110
	Met Glu Tyr Ser Gly Trp Ala Pro Ala Gly Ser Tyr Asp Gln Val Val	
	345 350 355	
55	atc cgc ggc gac gcg gcg aag cgc gag ttc atc gcc ttc tgg gtg aag	1158
	Ile Arg Gly Asp Ala Ala Lys Arg Glu Phe Ile Ala Phe Trp Val Lys	
	360 365 370 375	

EP 1 500 704 A1

5 gag ggc cgg gtg ctg gcc ggg atg aac gtc aac gtg tgg gac gtc acg 1206  
 Glu Gly Arg Val Leu Ala Gly Met Asn Val Asn Val Trp Asp Val Thr  
 380 385 390

gag ccg atc cag cag ctg atc cgc tgc aag acc cgg gtg gac acg gag 1254  
 Glu Pro Ile Gln Gln Leu Ile Arg Ser Lys Thr Arg Val Asp Thr Glu  
 395 400 405

10 gac ctg gcg aac ccg cac gta tcc ctc gaa agc ctc gtc gca 1296  
 Asp Leu Ala Asn Pro His Val Ser Leu Glu Ser Leu Val Ala  
 410 415 420

tagttgtcgg tccgcccccg tag 1319

15 <210> 14  
 <211> 421  
 <212> PRT  
 <213> Streptomyces coelicolor A3(2)

20 <400> 14  
 Val Val Asp Ala Asp Gln Thr Phe Val Ile Val Gly Gly Gly Leu Ala  
 1 5 10 15

25 Gly Ala Lys Ala Ala Glu Thr Leu Arg Thr Glu Gly Phe Thr Gly Arg  
 20 25 30

Val Ile Leu Val Cys Asp Glu Arg Asp His Pro Tyr Glu Arg Pro Pro  
 35 40 45

30 Leu Ser Lys Gly Tyr Leu Leu Gly Lys Glu Glu Arg Asp Ser Val Phe  
 50 55 60

Val His Glu Pro Ala Trp Tyr Ala Arg His Asp Ile Glu Leu His Leu  
 65 70 75 80

35 Gly Gln Thr Val Val Ala Ile Asp Arg Ala Ala Lys Thr Val His Tyr  
 85 90 95

Gly Asp Asp Gly Thr His Val Ser Tyr Asp Lys Leu Leu Ile Ala Thr  
 100 105 110

40 Gly Ala Glu Pro Arg Arg Leu Asp Val Pro Gly Thr Gly Leu Ala Gly  
 115 120 125

Val His His Leu Arg Arg Leu Ala His Ala Glu Arg Leu Lys Gly Val  
 130 135 140

45 Leu Ala Thr Leu Gly Arg Asp Asn Gly His Leu Val Ile Ala Gly Ala  
 145 150 155 160

Gly Trp Ile Gly Leu Glu Val Ala Ala Ala Ala Arg Glu Tyr Gly Ala  
 165 170 175

50 Glu Val Thr Val Ile Glu Pro Ala Pro Thr Pro Leu His Gly Val Leu  
 180 185 190

Gly Pro Glu Leu Gly Ala Val Phe Ala Glu Leu His Glu Ser Arg Gly  
 195 200 205

55 Val Arg Phe Arg Phe Gly Val Lys Leu Thr Glu Ile Val Gly Gln Asp  
 210 215 220

# EP 1 500 704 A1

Gly Val Val Leu Ala Ala Arg Thr Asp Asp Gly Glu Glu His Pro Ala  
 225 230 235 240  
 5 His Asp Val Leu Ala Ala Ile Gly Ala Ala Pro Arg Thr Ala Leu Ala  
 245 250 255  
 Gln Ala Ala Gly Leu Glu Ile Ala Asp Arg Ala His Gly Gly Gly Ile  
 260 265 270  
 10 Val Val Asp Asp His Leu Arg Thr Ser Asp Pro Asp Ile Phe Ala Ala  
 275 280 285  
 Gly Asp Val Ala Ser Phe His His Ala Leu Phe Asp Thr Ser Leu Arg  
 290 295 300  
 15 Val Glu His Trp Ala Asn Ala Leu Asn Gly Gly Pro Ala Ala Ala Arg  
 305 310 315 320  
 Ala Met Leu Gly Arg Gly Leu Ala His Asp Arg Val Pro Tyr Phe Phe  
 325 330 335  
 20 Thr Asp Gln Tyr Asp Leu Gly Met Glu Tyr Ser Gly Trp Ala Pro Ala  
 340 345 350  
 Gly Ser Tyr Asp Gln Val Val Ile Arg Gly Asp Ala Ala Lys Arg Glu  
 355 360 365  
 25 Phe Ile Ala Phe Trp Val Lys Glu Gly Arg Val Leu Ala Gly Met Asn  
 370 375 380  
 Val Asn Val Trp Asp Val Thr Glu Pro Ile Gln Gln Leu Ile Arg Ser  
 385 390 395 400  
 30 Lys Thr Arg Val Asp Thr Glu Asp Leu Ala Asn Pro His Val Ser Leu  
 405 410 415  
 35 Glu Ser Leu Val Ala  
 420

<210> 15  
 <211> 36  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PRR-1F Primer

<400> 15  
 gccccccata tgaacgcaaa cgacaacgtg gtcatc

36

<210> 16  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PRR-2R Primer

<400> 16

gcggatcctc aggcaactact cagttcagct ttggc 35

5 <210> 17  
 <211> 37  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Description of Artificial Sequence:Mox-1F Primer

<400> 17  
 gcccccccat atgacgaaga acgtcgccga cgaactg 37

15 <210> 18  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <223> Description of Artificial Sequence:Mox-12R Primer

<400> 18  
 gcagatctag tggcttcagg cgtcccgag gatgg 35

25 <210> 19  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Description of Artificial Sequence:Mox-2R Primer

<400> 19  
 cgactagtgg cttcaggcgt cccgcaggat gg 32

35 <210> 20  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <223> Description of Artificial Sequence:Mox-3F Primer

<400> 20  
 ggagatatatac atatgacgaa gaac 24

45 <210> 21  
 <211> 41  
 <212> DNA  
 <213> Artificial Sequence

50 <220>  
 <223> Description of Artificial Sequence:Mox-5R Primer

<400> 21  
 gccccccata tgacgcactc ctagtggctt caggcgtccc g 41

55

EP 1 500 704 A1

<210> 22  
 <211> 1950  
 <212> DNA  
 <213> Pseudomonas putida ATCC17453

<220>  
 <221> CDS  
 <222> (115)..(1383)

<220>  
 <221> CDS  
 <222> (1439)..(1759)

<400> 22  
 ccgggtgccc agattcagca caagagcggc atcgtcagcg gcgtgcaggc actccctctg 60

gtctgggatac cggcgactac caaagcggta taaacacatg ggagtgcgtg ctaa gtg 117  
 Val  
 1

aac gca aac gac aac gtg gtc atc gtc ggt acc gga ctg gct ggc gtt 165  
 Asn Ala Asn Asp Asn Val Val Ile Val Gly Thr Gly Leu Ala Gly Val  
 5 10 15

gag gtc gcc ttc ggc ctg cgc gcc agc ggc tgg gaa ggc aat atc cgg 213  
 Glu Val Ala Phe Gly Leu Arg Ala Ser Gly Trp Glu Gly Asn Ile Arg  
 20 25 30

ttg gtg ggg gat gcg acg gta att ccc cat cac cta cca ccg cta tcc 261  
 Leu Val Gly Asp Ala Thr Val Ile Pro His His Leu Pro Pro Leu Ser  
 35 40 45

aaa gct tac ttg gcc ggc aaa gcc aca gcg gaa agc ctg tac ctg aga 309  
 Lys Ala Tyr Leu Ala Gly Lys Ala Thr Ala Glu Ser Leu Tyr Leu Arg  
 50 55 60 65

acc cca gat gcc tat gca gcg cag aac atc caa cta ctc gga ggc aca 357  
 Thr Pro Asp Ala Tyr Ala Ala Gln Asn Ile Gln Leu Leu Gly Gly Thr  
 70 75 80

cag gta acg gct atc aac cgc gac cga cag caa gta atc cta tcg gat 405  
 Gln Val Thr Ala Ile Asn Arg Asp Arg Gln Gln Val Ile Leu Ser Asp  
 85 90 95

ggc cgg gca ctg gat tac gac cgg ctg gta ttg gct acc gga ggg cgt 453  
 Gly Arg Ala Leu Asp Tyr Asp Arg Leu Val Leu Ala Thr Gly Gly Arg  
 100 105 110

cca aga ccc cta ccg gtg gcc agt ggc gca gtt gga aag gcg aac aac 501  
 Pro Arg Pro Leu Pro Val Ala Ser Gly Ala Val Gly Lys Ala Asn Asn  
 115 120 125

ttt cga tac ctg cgc aca ctc gag gac gcc gag tgc att cgc cgg cag 549  
 Phe Arg Tyr Leu Arg Thr Leu Glu Asp Ala Glu Cys Ile Arg Arg Gln  
 130 135 140 145

ctg att gcg gat aac cgt ctg gtg gtg att ggt ggc ggc tac att ggc 597  
 Leu Ile Ala Asp Asn Arg Leu Val Val Ile Gly Gly Gly Tyr Ile Gly  
 150 155 160

ctt gaa gtg gct gcc acc gcc atc aag gcg aac atg cac gtc acc ctg 645  
 Leu Glu Val Ala Ala Thr Ala Ile Lys Ala Asn Met His Val Thr Leu  
 165 170 175

EP 1 500 704 A1

5	ctt gat acg gca gcc cgg gtt ctg gag cgg gtt acc gcc ccg ccg gta Leu Asp Thr Ala Ala Arg Val Leu Glu Arg Val Thr Ala Pro Pro Val	693
	180 185 190	
10	tcg gcc ttt tac gag cac cta cac cgc gaa gcc ggc gtt gac ata cga Ser Ala Phe Tyr Glu His Leu His Arg Glu Ala Gly Val Asp Ile Arg	741
	195 200 205	
15	acc ggc acg cag gtg tgc ggg ttc gag atg tcg acc gac caa cag aag Thr Gly Thr Gln Val Cys Gly Phe Glu Met Ser Thr Asp Gln Gln Lys	789
	210 215 220 225	
20	gtt acc gcc gtc ctc tgc gag gac ggc aca agg ctg cca gcg gat ctg Val Thr Ala Val Leu Cys Glu Asp Gly Thr Arg Leu Pro Ala Asp Leu	837
	230 235 240	
25	gta atc gcc ggg att ggc ctg ata cca aac tgc gag ttg gcc agt gcg Val Ile Ala Gly Ile Gly Leu Ile Pro Asn Cys Glu Leu Ala Ser Ala	885
	245 250 255	
30	gcc ggc ctg cag gtt gat aac ggc atc gtg atc aac gaa cac atg cag Ala Gly Leu Gln Val Asp Asn Gly Ile Val Ile Asn Glu His Met Gln	933
	260 265 270	
35	acc tct gat ccc ttg atc atg gcc gtc ggc gac tgt gcc cga ttt cac Thr Ser Asp Pro Leu Ile Met Ala Val Gly Asp Cys Ala Arg Phe His	981
	275 280 285	
40	agt cag ctc tat gac cgc tgg gtg cgt atc gaa tcg gtg ccc aat gcc Ser Gln Leu Tyr Asp Arg Trp Val Arg Ile Glu Ser Val Pro Asn Ala	1029
	290 295 300 305	
45	ttg gag cag gca cga aag atc gcc gcc atc ctc tgt ggc aag gtg cca Leu Glu Gln Ala Arg Lys Ile Ala Ala Ile Leu Cys Gly Lys Val Pro	1077
	310 315 320	
50	cgc gat gag gcg gcg ccc tgg ttc tgg tcc gat cag tat gag atc gga Arg Asp Glu Ala Ala Pro Trp Phe Trp Ser Asp Gln Tyr Glu Ile Gly	1125
	325 330 335	
55	ttg aag atg gtc gga ctg tcc gaa ggg tac gac cgg atc att gtc cgc Leu Lys Met Val Gly Leu Ser Glu Gly Tyr Asp Arg Ile Ile Val Arg	1173
	340 345 350	
60	ggc tct ttg gcg caa ccc gac ttc agc gtt ttc tac ctg cag gga gac Gly Ser Leu Ala Gln Pro Asp Phe Ser Val Phe Tyr Leu Gln Gly Asp	1221
	355 360 365	
65	cgg gta ttg gcg gtc gat aca gtg aac cgt cca gtg gag ttc aac cag Arg Val Leu Ala Val Asp Thr Val Asn Arg Pro Val Glu Phe Asn Gln	1269
	370 375 380 385	
70	tca aaa caa ata atc acg gat cgt ttg ccg gtt gaa cca aac cta ctc Ser Lys Gln Ile Ile Thr Asp Arg Leu Pro Val Glu Pro Asn Leu Leu	1317
	390 395 400	
75	ggt gac gaa agc gtg ccg tta aag gaa atc atc gcc gcc gcc aaa gct Gly Asp Glu Ser Val Pro Leu Lys Glu Ile Ile Ala Ala Ala Lys Ala	1365
	405 410 415	

EP 1 500 704 A1

gaa ctg agt agt gcc tga aatctatacc cacaataaat caccgttttg 1413  
 Glu Leu Ser Ser Ala  
 420

5 ccccatagcg tgtgaggata aacag atg tct aaa gta gtg tat gtg tca cat 1465  
 Met Ser Lys Val Val Tyr Val Ser His  
 425 430

10 gat gga acg cgt cgc gaa ctg gat gtg gcg gat ggc gtc agc ctg atg 1513  
 Asp Gly Thr Arg Arg Glu Leu Asp Val Ala Asp Gly Val Ser Leu Met  
 435 440 445

15 cag gct gca gtc tcc aat ggt atc tac gat att gtc ggt gat tgt ggc 1561  
 Gln Ala Ala Val Ser Asn Gly Ile Tyr Asp Ile Val Gly Asp Cys Gly  
 450 455 460

ggc agc gcc agc tgt gcc acc tgc cat gtc tat gtg aac gaa gcg ttc 1609  
 Gly Ser Ala Ser Cys Ala Thr Cys His Val Tyr Val Asn Glu Ala Phe  
 465 470 475 480

20 acg gac aag gtg ccc gcc gcc aac gag cgg gaa atc ggc atg ctg gag 1657  
 Thr Asp Lys Val Pro Ala Ala Asn Glu Arg Glu Ile Gly Met Leu Glu  
 485 490 495

25 tgc gtc acg gcc gaa ctg aag cgg aac agc agg ctc tgc tgc cag atc 1705  
 Cys Val Thr Ala Glu Leu Lys Pro Asn Ser Arg Leu Cys Cys Gln Ile  
 500 505 510

atc atg acg ccc gag ctg gat ggc atc gtg gtc gat gtt ccc gat agg 1753  
 Ile Met Thr Pro Glu Leu Asp Gly Ile Val Val Asp Val Pro Asp Arg  
 515 520 525

30 caa tgg taaaccacaa tggtaaacca ctgcgagcca aaacagccga gcaggagcgc 1809  
 Gln Trp  
 530

agtcgggcaa caccttatta agcacatgcc gaacctatt tgcagcgctt catgcctgca 1869

35 aagtcccgat tgatgaaatc cgggctccaa gcaaggagcc cggaatctct caccgccacg 1929

aaatcaatgg ccaatcccgg g 1950

<210> 23  
 <211> 422  
 <212> PRT  
 <213> Pseudomonas putida ATCC17453

<400> 23

45 Val Asn Ala Asn Asp Asn Val Val Ile Val Gly Thr Gly Leu Ala Gly  
 1 5 10 15  
 Val Glu Val Ala Phe Gly Leu Arg Ala Ser Gly Trp Glu Gly Asn Ile  
 20 25 30  
 Arg Leu Val Gly Asp Ala Thr Val Ile Pro His His Leu Pro Pro Leu  
 35 40 45  
 Ser Lys Ala Tyr Leu Ala Gly Lys Ala Thr Ala Glu Ser Leu Tyr Leu  
 50 55 60  
 Arg Thr Pro Asp Ala Tyr Ala Ala Gln Asn Ile Gln Leu Leu Gly Gly  
 65 70 75 80  
 Thr Gln Val Thr Ala Ile Asn Arg Asp Arg Gln Gln Val Ile Leu Ser  
 85 90 95  
 Asp Gly Arg Ala Leu Asp Tyr Asp Arg Leu Val Leu Ala Thr Gly Gly  
 100 105 110

EP 1 500 704 A1

Arg Pro Arg Pro Leu Pro Val Ala Ser Gly Ala Val Gly Lys Ala Asn  
 115 120 125  
 Asn Phe Arg Tyr Leu Arg Thr Leu Glu Asp Ala Glu Cys Ile Arg Arg  
 130 135 140  
 5 Gln Leu Ile Ala Asp Asn Arg Leu Val Val Ile Gly Gly Gly Tyr Ile  
 145 150 155 160  
 Gly Leu Glu Val Ala Ala Thr Ala Ile Lys Ala Asn Met His Val Thr  
 165 170 175  
 10 Leu Leu Asp Thr Ala Ala Arg Val Leu Glu Arg Val Thr Ala Pro Pro  
 180 185 190  
 Val Ser Ala Phe Tyr Glu His Leu His Arg Glu Ala Gly Val Asp Ile  
 195 200 205  
 Arg Thr Gly Thr Gln Val Cys Gly Phe Glu Met Ser Thr Asp Gln Gln  
 210 215 220  
 15 Lys Val Thr Ala Val Leu Cys Glu Asp Gly Thr Arg Leu Pro Ala Asp  
 225 230 235 240  
 Leu Val Ile Ala Gly Ile Gly Leu Ile Pro Asn Cys Glu Leu Ala Ser  
 245 250 255  
 Ala Ala Gly Leu Gln Val Asp Asn Gly Ile Val Ile Asn Glu His Met  
 260 265 270  
 20 Gln Thr Ser Asp Pro Leu Ile Met Ala Val Gly Asp Cys Ala Arg Phe  
 275 280 285  
 His Ser Gln Leu Tyr Asp Arg Trp Val Arg Ile Glu Ser Val Pro Asn  
 290 295 300  
 Ala Leu Glu Gln Ala Arg Lys Ile Ala Ala Ile Leu Cys Gly Lys Val  
 305 310 315 320  
 25 Pro Arg Asp Glu Ala Ala Pro Trp Phe Trp Ser Asp Gln Tyr Glu Ile  
 325 330 335  
 Gly Leu Lys Met Val Gly Leu Ser Glu Gly Tyr Asp Arg Ile Ile Val  
 340 345 350  
 Arg Gly Ser Leu Ala Gln Pro Asp Phe Ser Val Phe Tyr Leu Gln Gly  
 355 360 365  
 30 Asp Arg Val Leu Ala Val Asp Thr Val Asn Arg Pro Val Glu Phe Asn  
 370 375 380  
 Gln Ser Lys Gln Ile Ile Thr Asp Arg Leu Pro Val Glu Pro Asn Leu  
 385 390 395 400  
 Leu Gly Asp Glu Ser Val Pro Leu Lys Glu Ile Ile Ala Ala Ala Lys  
 405 410 415  
 35 Ala Glu Leu Ser Ser Ala  
 420

<210> 24  
 <211> 107  
 <212> PRT  
 <213> Pseudomonas putida ATCC17453

<400> 24  
 Met Ser Lys Val Val Tyr Val Ser His Asp Gly Thr Arg Arg Glu Leu  
 1 5 10 15  
 45 Asp Val Ala Asp Gly Val Ser Leu Met Gln Ala Ala Val Ser Asn Gly  
 20 25 30  
 Ile Tyr Asp Ile Val Gly Asp Cys Gly Gly Ser Ala Ser Cys Ala Thr  
 35 40 45  
 50 Cys His Val Tyr Val Asn Glu Ala Phe Thr Asp Lys Val Pro Ala Ala  
 50 55 60  
 Asn Glu Arg Glu Ile Gly Met Leu Glu Cys Val Thr Ala Glu Leu Lys  
 65 70 75 80  
 Pro Asn Ser Arg Leu Cys Cys Gln Ile Ile Met Thr Pro Glu Leu Asp  
 85 90 95  
 55 Gly Ile Val Val Asp Val Pro Asp Arg Gln Trp  
 100 105

5  
 <210> 25  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <223> Description of Artificial Sequence:SP-1

<400> 25  
 tatgcgtcac tagtcgggag tgcgtta 27

15  
 <210> 26  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

20  
 <220>  
 <223> Description of Artificial Sequence:SP-2

<400> 26  
 tataacgcac tcccgactag tgacgca 27

25  
 <210> 27  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

30  
 <220>  
 <223> Description of Artificial Sequence:CB-4F Primer

<400> 27  
 gccccccata tgacagcttt gaatctgatg 30

35  
 <210> 28  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

40  
 <220>  
 <223> Description of Artificial Sequence:CB-5R Primer

<400> 28  
 gcactagtca gagacggacc ggcagac 27

45  
 <210> 29  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

50  
 <220>  
 <223> Description of Artificial Sequence:l54A1-1F

<400> 29  
 gccccccata tggcgaccca gcagcccgcc etc 33

55  
 <210> 30

<211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:154A1-2R Primer

<400> 30  
 gcactagtca gccggcgtgc agcaggaccg g 31

<210> 31  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:DoxA-1F Primer

<400> 31  
 gccccccata tggccgtcga cccgttcgcg tg 32

<210> 32  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:DoxA-2R Primer

<400> 32  
 gcactagtca gcgcagccag acgggcagtt c 31

# Claims

1. A system for the expression of actinomycete cytochrome P-450 genes in host *Escherichia coli*, wherein said *Escherichia coli* supports a recombinant DNA molecule which comprises xenogenic microorganism-originated ferredoxin gene, ferredoxin reductase gene as well as said cytochrome P-450 gene, in operable state.
2. An expression system of claim 1 wherein ferredoxin gene and ferredoxin reductase gene are independently originated from some strain of actinomycete.
3. An expression system of claim 1 wherein ferredoxin gene is originated from microorganism selected from the group consisting of those belonging to genus *Microtetraspora* and those belonging to genus *Pseudomonas*.
4. An expression system of claim 1 wherein ferredoxin reductase gene is originated from microorganism selected from the group consisting of those belonging to genus *Streptomyces* and those belonging to genus *Pseudomonas*.
5. An expression system of claim 1 wherein actinomycete cytochrome P-450 gene and ferredoxin gene are originated from one and the same gene cluster of actinomycete.
6. An expression system of claim 1 wherein ferredoxin reductase gene is originated from *Streptomyces coelicolor*.

7. An expression system of claim 1 wherein actinomycete cytochrome P-450 gene and ferredoxin gene are originated from one and the same gene cluster of actinomycete, and wherein ferredoxin reductase gene is originated from *Streptomyces coelicolor*.
- 5 8. An expression system of claim 1 wherein ferredoxin gene and ferredoxin reductase gene are respectively putidaredoxin gene (*camB*) and putidaredoxin reductase gene (*camA*) which are each originated from *Pseudomonas putida*.
- 10 9. An expression system of claim 1 in which actinomycete cytochrome P-450 gene and ferredoxin gene are originated from one and the same gene cluster of actinomycete, and which further contains, as another ferredoxin gene, putidaredoxin gene (*camB*) originated from *Pseudomonas putida*.
- 15 10. An expression system of claim 1 in which actinomycete cytochrome P-450 gene and ferredoxin gene are originated from one and the same gene cluster of actinomycete, in which ferredoxin reductase gene is putidaredoxin reductase gene (*camA*) originated from *Pseudomonas putida*, and which further contains, as another ferredoxin gene, putidaredoxin gene (*camB*) originated from *Pseudomonas putida*.
- 20 11. An expression system of claim 1 wherein actinomycete cytochrome P-450 gene and ferredoxin gene are respectively compactin-hydroxylating enzyme-encoding gene (*moxA*) originated from *Microtetraspora recticattina* and ferredoxin gene (*moxB*) which is adjacent downstream to *moxA*.
- 25 12. An expression system of claim 1 wherein actinomycete cytochrome P-450 gene and ferredoxin gene are respectively compactin-hydroxylating enzyme-encoding gene (*moxA*) originated from *Microtetraspora recticattina* and ferredoxin gene (*moxB*) which is adjacent downstream to *moxA*, and wherein ferredoxin reductase gene is ferredoxin reductase gene *fdr-1* or *fdr-2* originated from *Streptomyces coelicolor*.
- 30 13. An expression system of claim 1 in which actinomycete cytochrome P-450 gene and ferredoxin gene are respectively compactin-hydroxylating enzyme-encoding gene (*moxA*) originated from *Microtetraspora recticattina* and ferredoxin gene (*moxB*) adjacent downstream to *moxA*, and which further contains, as another ferredoxin gene, putidaredoxin gene (*camB*) originated from *Pseudomonas putida*, and in which ferredoxin reductase gene is putidaredoxin reductase gene (*camA*) originated from *Pseudomonas putida*.
- 35 14. An expression system of claim 1 in which the induction of expression of cytochrome P-450 gene is conveniently carried out at 20 to 24°C.
- 40 15. An expression system of claim 1 wherein said cytochrome P-450 gene comprises polynucleotide which is selected from the group consisting of polynucleotide having a continuous nucleotide sequence from base 313 to base 1533 in Sequence No. 1 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence, and polynucleotide having a continuous nucleotide sequence from base 544 to base 1758 in Sequence No. 2 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence.
- 45 16. An expression system of claim 1 wherein said ferredoxin gene comprises polynucleotide which is selected from the group consisting of polynucleotide having a continuous nucleotide sequence from base 1547 to base 1741 in Sequence No. 1 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence, and polynucleotide having a continuous nucleotide sequence from base 1782 to base 1970 in Sequence No. 2 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence.
- 50 17. An expression system of claim 1 wherein said ferredoxin reductase gene comprises polynucleotide which is selected from the group consisting of polynucleotide having a continuous nucleotide sequence from base 118 to base 1377 in Sequence No. 5 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence, and polynucleotide having a continuous nucleotide sequence from base 34 to base 1296 in Sequence No. 8 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence.
- 55 18. An expression system of claim 1 wherein said ferredoxin gene comprises polynucleotide having a continuous nucleotide sequence from base 1439 to base 1759 in Sequence No. 16 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence.
19. An expression system of claim 1 wherein said ferredoxin reductase gene comprises polynucleotide having a con-

tinuous nucleotide sequence from base 115 to base 1380 in Sequence No. 16 or functionally equivalent polynucleotide with homology of at least 80 % to said nucleotide sequence.

- 5      **20.** A method to introduce a hydroxyl group at 6 $\beta$ -position of compactin with use of the expression system of claim 12 or 13.

10

15

20

25

30

35

40

45

50

55

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/04609

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> C12N15/70, C12N15/53, C12N15/12, C12P7/62 // C12N15/53, C12N1/21, (C12N15/70, C12R1:04), (C12N15/53, C12R1:38), (C12N15/12, C12R1:465), (C12N15/12, C12R1:38), According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N15/00-90, C12P1/00-41/00, C12N1/00-38, C12N9/00-99  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE (STN), WPI (DIALOG), BIOSIS (DIALOG), GenBank/EMBL/DBJ/GeneSeq, SwissProt/PIR/GeneSeq		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	JP 07-067666 A (Sumitomo Chemical Co., Ltd.), 14 March, 1995 (14.03.95), & EP 477961 A1 & US 5668000 A	1-10, 14 11-13, 15-20
Y A	WO 93/12236 A1 (E.I. DU PONT DE NEMOURS & CO.), 24 June, 1993 (24.06.93), & JP 07-502650 A & EP 618972 A1 & US 5466590 A	1-10, 14 11-13, 15-20
Y	Peterson J.A. et al., "Putidaredoxin reductase and putidaredoxin. Cloning, sequence determination, and heterologous expression of the proteins.", J.Biol.Chem.(1990), Vol.265, No.11, pages 6066 to 6073	3, 4, 8-10
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 06 May, 2003 (06.05.03)		Date of mailing of the international search report 27 May, 2003 (27.05.03)
Name and mailing address of the ISA/ Japanese Patent Office  Facsimile No.		Authorized officer  Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/04609

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/19917 A1 (L'OREAL SA), 05 June, 1997 (05.06.97), & JP 10-504845 A & EP 805800 A1 & US 6278001 B1	20

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/04609

Continuation of A. CLASSIFICATION OF SUBJECT MATTER  
(International Patent Classification (IPC))

Int.Cl<sup>7</sup> (C12P7/62, C12R1:19), (C12N1/21, C12R1:19)

(According to International Patent Classification (IPC) or to both  
national classification and IPC)